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Abstract:
Background—MicroRNAs are key regulators of angiogenic processes. Administration of 
angiogenic early outgrowth cells (EOCs) or CD34+-cells has been suggested to improve cardiac 
function after ischemic injury in particular by promoting neovascularization. The present study 
therefore examines regulation of angiomiRs, microRNAs involved in angiogenesis, in 
angiogenic-EOCs and circulating CD34+-cells from patients with chronic heart failure (CHF) 
and the role for their cardiac repair capacity.
Methods and Results—Angiogenic-EOCs and CD34+-cells were isolated from patients with 
CHF due to ischemic cardiomyopathy (n=45) and healthy subjects (HS; n=35). In flow-
cytometry analyses angiogenic-EOCs were largely myeloid and positive for alternatively-
activated, M2-macrophage markers.  In vivo cardiac neovascularization and functional repair 
capacity were examined after transplantation into nude mice with myocardial infarction (MI). 
Cardiac transplantation of angiogenic-EOCs from HS markedly increased neovascularization and 
improved cardiac function, whereas no such effect was observed after transplantation of 
angiogenic-EOCs from patients with CHF. RT-PCR analysis of 14 candidate angiomiRs, 
expressed in angiogenic-EOCs, revealed a pronounced loss of angiomiR-126 and -130a in 
angiogenic-EOCs from patients with CHF, that was also observed in circulating CD34+-cells.
Anti-miR-126 transfection markedly impaired the capacity of angiogenic-EOCs from HS to 
improve cardiac function.  miR-126-mimic transfection increased the capacity of angiogenic-
EOCs from patients with CHF to improve cardiac neovascularization and function.
Conclusions—The present study reveals a loss of angiomiR-126 and -130a in angiogenic-EOCs 
and circulating CD34+-cells from patients with CHF.  Reduced miR-126 expression was 
identified as a novel mechanism limiting their capacity to improve cardiac neovascularization 
and function that can be targeted by miR-126-mimic-transfection.
Key words: chronic heart failure; endothelial progenitor cells; ischemic cardiomyopathy; 
microRNA; angiogenic early outgrowth cells 
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Introduction
MicroRNAs (miRNAs), small non-coding RNAs regulating gene expression at the post-
transcriptional level, have recently been identified as key regulators of angiogenic processes.1-4
Endothelial silencing of Dicer, an RNase-III-enzyme required for generation of mature miRNAs, 
revealed a critical role of miRNAs for in vitro and in vivo angiogenic processes.5, 6 Furthermore, 
individual miRNAs, including miR-126, miR-130a, let-7f and the miR-17-92 cluster, have been 
identified as key positive or negative regulators of angiogenic processes.5, 7-13 ?
Accumulating data suggest that bone marrow-derived mononuclear cells are important 
regulators of cardiac neovascularization.14-24 In particular, several studies have demonstrated that 
administration of angiogenic early outgrowth cells (angiogenic EOCs), also known as circulating 
angiogenic cells, or CD34+-cells stimulate myocardial neovascularization and improve cardiac 
function after experimental myocardial infarction (MI).14-16, 18, 21 Moreover, Fazel et al. have 
reported that in mice with a mutation of the c-kit receptor, leading to an impaired mobilization of 
bone marrow-derived progenitor cells post-MI, cardiac neovascularization was substantially 
impaired associated with an augmented LV-dysfunction post-MI, suggesting an important role of 
bone marrow-derived mononuclear cells for the endogenous cardiac repair response.19  More 
recently, two studies have supported the concept that pro-angiogenic effects of bone marrow-
derived mononuclear cells or CD34+-cells are crucial for their capacity to improve cardiac 
function, using either selective elimination of eNOS or anti-VEGF treatment.23, 24 Of note, in the 
TOPCARE-AMI study a beneficial effect of administration of angiogenic EOCs on cardiac 
function was observed in patients with an acute myocardial infarction,25 whereas no such effect 
was detected in patients with an ischemic cardiomyopathy.26
The present study was therefore designed to characterize regulation of angiomiRs in 
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angiogenic EOCs and circulating CD34+-cells from patients with CHF due to ischemic 
cardiomyopathy and to determine their role for the in vivo cardiac neovascularization and 
functional cardiac repair capacity, as examined after transplantation of angiogenic EOCs into 
nude mice with myocardial infarction. 
Methods
An expanded description of methods is available in the online data supplement.
Characteristics of Patients with CHF and Healthy Subjects 
Written informed consent was obtained from all patients and healthy subjects, and the study 
protocol was approved by the local ethics committee.  Angiogenic EOCs and CD34+-cells were 
isolated from venous blood from patients with chronic heart failure (CHF) due to ischemic 
cardiomyopathy (ICM; n=45) with left ventricular ejection fraction (LVEF) < 40% and age-
matched healthy subjects (HS; n=35).  HS had no cardiovascular risk factors (according to 
history, clinical examination, and laboratory tests) or accompanying disorders.???In addition, 15 
patients with CHF due to dilated cardiomyopathy without significant coronary stenosis and an 
LVEF < 40% were included to further examine the effects of CHF independent of ischemic heart 
disease on angiomiR expression of angiogenic EOCs and CD34+-cells. Patient characteristics are 
shown in Table 1.
Isolation and Cultivation of Angiogenic EOCs and CD34+-cells 
Angiogenic EOCs were isolated and cultured as described in detail previously27-29 and in 
supplemental methods. Angiogenic EOCs were carefully characterized by flow-cytometry 
analysis, revealing that the majority of these cells are myeloid and express alternatively-
activated, M2-macrophage markers (Supplemental Figure 1, Supplemental Tables 1-3). For 
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isolation of CD34+-cells, mononuclear cells were magnetically labeled with CD34-beads and 
separated using a MACS-column and a MACS-separator according to manufacturer`s 
instructions (Miltenyi-Biotec).
Animals, Myocardial Infarction and Cell Transplantation 
Animal experiments were approved by the local committee. Myocardial infarction (MI) was 
induced by permanent ligation of left-anterior-descending-coronary-artery in male NMRI-nu/nu-
mice, as described in detail previously.27, 30, 31 Ten minutes post-MI, 5x105 human angiogenic 
EOCs or placebo (i.e. same volume of PBS-buffer) were injected intramyocardially into the 
infarct border zone at 4 sites using a 30G needle.  Cardiac function was examined by cardiac 
MRI and Millar-catheter hemodynamic measurements.  For details see supplemental methods. 
Statistical Analysis 
For comparison of three or more groups, the Levene test was used to test for variance 
heterogeneity. If variance differed significantly between the groups the Welch’s ANOVA test 
was used with Dunnett-T3 test as a post-hoc test. One-way ANOVA followed by Tukey-Kramer 
test was performed for comparisons between groups with homogenous variance.  For comparison 
of two groups, variance heterogeneity was tested with Levene test followed by t-test or unpaired 
t-test with Welch’s correction, depending on equal or unequal variances, respectively. If there 
was a non-normal distribution Kruskal-Wallis and Mann-Whitney-U-test were used. All data are 
expressed as mean±SEM. A p-value of < 0.05 was considered statistically significant. Data were 
analyzed by using SPSS-20.0.
Results
Cardiac Neovascularization and Repair Capacity of Angiogenic EOCs are Substantially 
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Impaired in Patients with CHF due to ICM 
Cardiac transplantation of angiogenic EOCs from HS into nude mice after myocardial infarction 
improved LVEF and augmented cardiac function (dPdtmax), as determined by cardiac MRI and 
cardiac hemodynamic analysis using the Millar catheter (Figure 1A-C; Table 2).  In contrast, no 
significant effects on these parameters were observed after transplantation of the same number of 
angiogenic EOCs from patients with CHF due to ICM (Figure 1A-C, Table 2).
Capillary density (infarct border zone) was significantly increased after transplantation of 
angiogenic EOCs from HS, but not after transplantation of angiogenic EOCs from patients with 
CHF due to ICM (Figure 1D), suggesting impaired pro-angiogenic effects of angiogenic EOCs 
from these patients.   
In vivo bioluminescence imaging suggested a similar cell survival of angiogenic EOCs 
from HS or patients with CHF on day 1 and 3 after cardiac transplantation (Figure 1E),
consistent with the notion that impaired function may contribute to an impaired cardiac repair 
capacity of angiogenic EOCs from patients with CHF.  Similarly, there was no significant 
difference of the bioluminescence signal of explanted hearts on day 3 after transplantation of 
angiogenic EOCs from HS or patients with CHF, and no significant bioluminescence signal was 
detected in other organs (Supplemental Figure 2C). Ex vivo experiments indicated a close 
relation between increasing cell numbers and the bioluminescence signal (Supplemental Figure 
2B).  Confocal microscopy imaging of Dil-labeled angiogenic EOCs detected transplanted 
angiogenic EOCs in close vicinity to cardiac microvasculature of the infarct border zone 
(Supplemental Figure 3).
These findings suggested a functional impairment of transplanted angiogenic EOCs from 
patients with CHF with respect to their capacity to promote in vivo cardiac neovascularization. 
 at Universitaet Zuerich on December 17, 2012http://circ.ahajournals.org/Downloaded from 
DOI: 10.1161/CIRCULATIONAHA.112.093906 
7
We therefore determined differential expression of angiomiRs, i.e. miRNAs regulating 
angiogenic processes, using real-time PCR analysis.  
Expression of AngiomiRs miR-126 and miR-130a is Substantially Reduced in Angiogenic 
EOCs from Patients with CHF due to ICM 
First we performed a miRNA-array to detect angiomiRs expressed in angiogenic EOCs from HS 
(Supplemental Table 4A). The expression of fourteen miRNAs, that were expressed in 
angiogenic EOCs and had a potentially important role in angiogenesis, was compared between 
angiogenic EOCs from HS and patients with CHF due to ICM by using real-time-PCR analysis 
(Figure 2).  Notably, there was a marked loss of expression of potentially pro-angiogenic miR-
126 and miR-130a in angiogenic EOCs from patients with CHF due to ICM (Figure 2). In 
addition, expression of potentially anti-angiogenic miR-20a from miR 17-92 cluster was 
increased in angiogenic EOCs from patients with CHF (Figure 2). Due to the pronounced loss of 
miR-126 and miR-130a expression in angiogenic EOCs from patients with CHF we further 
examined their role for pro-angiogenic effects of angiogenic EOCs and their capacity to improve 
cardiac function.
Role of miR-126 and miR-130a for Angiogenic Capacity of Angiogenic EOCs in Vitro
Angiogenic effects of angiogenic EOCs were first characterized in co-cultures with human aortic 
endothelial cells.  Angiogenic EOCs from HS markedly stimulated tube formation, whereas no 
such effect was observed using angiogenic EOCs from patients with CHF (Figure 3A). Notably, 
anti-miR-126 and anti-miR-130a, but not scrambled-miR transfection of angiogenic EOCs from 
HS impaired their stimulating effects on tube formation in vitro (Figure 3B, for information on 
the anti-miR-sequences see Supplemental Table 5), indicating a role for both miRNAs for pro-
angiogenic effects.  Conversely, miR-126-mimic or miR-130a-mimic transfection of angiogenic 
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EOCs from patients with CHF due to ICM markedly enhanced their capacity to promote tube 
formation in vitro as compared to scrambled-miR transfected EOCs (26.1±4.8% vs. 8.8±4.5%; 
P<0.05 and 26.4±5.2% vs. 8.8±4.5%, P<0.05, n=7-8, for information on the miR-mimic-
sequences see Supplemental Table 6).  We have further examined effects of miR-126-mimic 
and miR-130a-mimic transfection of angiogenic EOCs from HS on their capacity to promote 
tube formation in vitro, however, no significant effects on the capacity of angiogenic EOCs from 
HS to promote tube formation were observed (Supplemental Figure 4), although there was a 
trend for miR-126-mimic transfected angiogenic EOCs from HS for an improved pro-angiogenic 
effect.   A possible explanation for this observation, i.e. the more pronounced effects of miR-
126-mimic and miR-130a-mimic transfection on pro-angiogenic capacity of angiogenic EOCs 
from patients with CHF as compared to angiogenic EOCs from HS could be the up-regulation of 
respective targets of these miRNAs in angiogenic EOCs from patients with CHF (Figure 3C).
We further examined the role of potential targets of miR-126 and miR-130a in angiogenic 
EOCs for their pro-angiogenic effects.  SPRED1 has been identified as a critical target for pro-
angiogenic effects of miR-126 in endothelial cells.7, 8  HOXA5, a target of miR-130a, is a 
negative regulator of angiogenesis in endothelial cells.11  Notably, both SPRED1 and HOXA5 
expression were substantially up-regulated in angiogenic EOCs from patients with CHF due to 
ICM, both on mRNA and protein levels (Figure 3C, for RT-PCR-primer-sequences see
Supplemental Table 7). Notably, silencing of SPRED1 and HOXA5 in angiogenic EOCs from 
patients with CHF due to ICM enhanced their pro-angiogenic capacity in the tube formation 
assay (Figure 3D-E), suggesting that up-regulation of these respective miRNA-targets 
contributes to impaired pro-angiogenic effects of angiogenic EOCs from these patients.
In line with these observations, anti-miR-126, but not scrambled-miR transfection of 
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angiogenic EOCs from HS impaired their capacity to stimulate microvessel outgrowth of aortic 
rings (7.5±7.6% vs. 44.9±9.0%; P<0.05. n=6).  There was no statistically significant difference 
with respect to effects of anti-miR-130a or scrambled-miR transfection of angiogenic EOCs from 
HS on microvessel outgrowth in the aortic ring assay, however, a trend towards an impaired 
endothelial outgrowth using anti-miR-130a was observed (26.2±10.2% versus 44.9±9.0%, 
P=n.s., n=6). 
Taken together, these in vitro analyses suggested a potential role of down-regulation of 
miR-126 and miR-130a for the impaired pro-angiogenic capacity of angiogenic EOCs from 
patients with CHF.  We therefore next determined effects of anti-miR-126 and anti-miR-130a 
transfection of angiogenic EOCs from HS as well as miR-126-mimic and miR-130a-mimic 
transfection of angiogenic EOCs from patients with CHF on their capacity to improve cardiac 
neovascularization and cardiac function.
Role of miR-126 and miR-130a for the Capacity of Angiogenic EOCs to Improve 
Neovascularization and Cardiac Function in Vivo
First, angiogenic EOCs from HS were transfected with anti-miR-126, anti-miR-130a or 
scrambled-miR.  Notably, anti-miR-126 transfection markedly impaired the capacity of 
angiogenic EOCs from HS to improve LVEF as assessed by cardiac MRI and to augment cardiac 
function as determined by hemodynamic analyses (dPdtmax) as compared to scrambled-miR 
transfection (Figure 4A-B, Table 3).  Moreover, anti-miR-126 transfection of angiogenic EOCs 
from HS impaired their capacity to promote cardiac neovascularization as compared to 
scrambled-miR transfection (Figure 4C).
In our in vivo bioluminescence imaging experiments no significant difference in cardiac 
survival of anti-miR-126 transfected or scrambled-miR transfected angiogenic EOCs from HS 
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was detected on day 1 and 3 after transplantation (Figure 4D), supporting the concept of a 
functional abnormality of anti-miR-126 transfected angiogenic EOCs.   
Anti-miR-130a transfected angiogenic EOCs had an impaired capacity to improve cardiac 
neovascularization (infarct border-zone) or cardiac function as assessed by hemodynamic 
analyses (dPdtmax) (Figure 4B-C).  There was a trend for a reduced effect of anti-miR-130a 
transfected angiogenic EOCs from HS on cardiac function as examined by cardiac MRI, 
however, this did not reach statistical significance (Figure 4A).
Subsequently, the effect of miR-126-mimic and miR-130a-mimic transfection on the 
capacity of angiogenic EOCs from patients with CHF to stimulate cardiac neovascularization and 
to improve cardiac function was examined.  miR-126-mimic transfection of angiogenic EOCs 
from patients with CHF significantly increased their capacity to improve cardiac function, as 
shown by cardiac MRI and hemodynamic analysis (dPdtmax), as compared to scrambled-miR 
transfection (Figure 5A-B, Table 4).  Moreover, miR-126-mimic transfected angiogenic EOCs 
from patients with CHF significantly improved neovascularization in the infarct border-zone as 
compared to scrambled-miR transfection (Figure 5C).  In studies using miR-130a-mimic 
transfected angiogenic EOCs from patients with CHF no significant changes with respect to their 
capacity to stimulate cardiac repair and neovascularization were observed as compared to 
scrambled-miR transfection, although there was a trend towards an improved capacity to 
stimulate cardiac repair and neovascularization (Figure 5A-C).  Of note, over-expression of 
miR-126 and miR-130a significantly increased the respective miRNA-expression levels of 
transfected angiogenic EOCs (Supplemental Figure 5). The flow-cytometry analysis of surface 
marker expression of angiogenic EOCs did not reveal significant changes after miR-mimic-
126/130a or anti-miR-126/130a transfection (Supplemental Tables 1-3).  
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Circulating CD34+-cells from Patients with CHF have Substantially Reduced miR-126 and 
miR-130a Levels 
To examine, whether observed changes in miR-126 and miR-130a expression are also present in 
freshly isolated circulating CD34+-cells, miR-126 and miR-130a expression were determined in 
circulating CD34+-cells from patients with CHF due to ICM and HS.  Notably, the expression of 
both miRNAs was substantially reduced in circulating CD34+-cells from patients with CHF due 
to ICM as compared to CD34+-cells from HS (Figure 6A). Moreover, expression of SPRED1 
and HOXA5, important respective targets of these miRNAs, were markedly up-regulated in 
circulating CD34+-cells from patients with CHF due to ICM (Figure 6A). These observations 
were associated with a markedly impaired pro-angiogenic capacity of CD34+-cells from patients 
with CHF due to ICM (Figure 6B).
To further examine whether down-regulation of miR-126 and miR-130a was limited to 
patients with CHF due to ICM, we also compared expression of miR-126 and miR-130a in 
angiogenic EOCs and circulating CD34+-cells from patients with CHF due to dilated 
cardiomyopathy (DCM) and HS. The expression of both miRNAs was substantially reduced in 
angiogenic EOCs and CD34+-cells from patients with CHF due to DCM (Supplemental Figure 
6A, 7A). Moreover, we examined EGF-like-domain-7 (EGFL7) expression, the gene encoding 
miR-126.8 There was a trend towards a lower EGFL7-mRNA-expression of angiogenic EOCs 
from patients with CHF due to ICM or DCM as compared to angiogenic EOCs from HS, 
however this did not reach statistical significance (Supplemental Figure 8).
Furthermore, up-regulation of important targets of both miRNAs was observed in angiogenic 
EOCs and CD34+-cells from patients with CHF due to DCM (Supplemental Figure 6A, 7A).  In 
addition, the pro-angiogenic capacity of angiogenic EOCs and CD34+-cells from patients with 
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CHF due to DCM was markedly impaired (Supplemental Figure 6B, 7B).  Of note, angiogenic 
EOCs from patients with CHF due to ICM and DCM showed similar expression levels of miR-
126 and miR-130a and their respective targets SPRED1 and HOXA5 (Supplemental Figure 9).
Discussion
MicroRNAs (miRNAs) have been identified as critical regulators of angiogenic processes. 
Experimental and clinical studies have suggested that administration of angiogenic EOCs or 
CD34+-cells can improve cardiac function following ischemic injury that is attributed in 
particular to their capacity to promote cardiac neovascularization.23, 24
In the present study we have observed a substantial down-regulation of angiomiRs miR-
126 and miR-130a in angiogenic EOCs and circulating CD34+-cells from patients with CHF, 
associated with up-regulation of direct downstream targets of these miRNAs.  Furthermore, 
cardiac transplantation of angiogenic EOCs from HS promoted myocardial neovascularization 
and improved cardiac function, but no such effects were observed after transplantation of 
angiogenic EOCs from patients with CHF, indicating a markedly impaired cardiac repair 
capacity of angiogenic EOCs from these patients.  Moreover, targeted delivery of anti-miR-126 
to angiogenic EOCs from HS impaired their capacity to improve myocardial neovascularization 
and cardiac function after ischemic injury in vivo, whereas miR-126-mimic transfection of 
angiogenic EOCs from patients with CHF increased their capacity to improve myocardial 
neovascularization and cardiac function, suggesting a predominant role of a reduced expression 
of this miRNA for their impaired cardiac repair capacity.  These findings provide novel insights 
into molecular mechanisms regulating angiogenic and cardiac repair capacity of angiogenic 
EOCs and their profound alterations in patients with CHF that can be targeted using miR-mimic 
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transfection.
Several studies have reported that administration of angiogenic EOCs or circulating 
CD34+-cells can enhance myocardial neovascularization and improve cardiac function.15, 16, 18, 21, 
32  Recent experimental studies have suggested that angiogenic effects of transplanted bone 
marrow-derived or CD34+-cells are critical for their capacity to promote cardiac repair.23, 24
Yoon et al. have reported that activation of an inducible suicide gene under the control of the 
endothelial NO synthase, but not the cardiomyocyte promoter alphaMHC in bone marrow-
derived mononuclear cells after cardiac transplantation resulted in reduced effects of BMC 
transplantation on cardiac neovascularization and function post-MI.23 Wang et al. have observed 
that improvement in cardiac neovascularization and function after cardiac CD34+- cell 
transplantation in mice post-MI was prevented by co-treatment with specific anti-VEGF 
antibodies, but not with anti-?4?1 antibodies, further suggesting that angiogenic effects, but not 
myogenesis, was responsible for functional improvements following CD34+-cell
transplantation.24 In addition, impaired mobilization of bone marrow-derived progenitor cells 
after experimental MI was associated with a substantially impaired cardiac neovascularization 
and augmented LV-dysfunction,19  supporting an important role of angiogenic effects of bone 
marrow-derived progenitor cells for endogenous cardiac repair responses after ischemic injury.   
The present study demonstrates that angiogenic EOCs from patients with CHF, in 
contrast to angiogenic EOCs from HS, have lost the capacity to promote myocardial 
neovascularization and improve cardiac function after ischemic injury in vivo.  Our findings 
further provide novel insights by demonstrating that altered angiomiR expression in angiogenic 
EOCs from patients with CHF is on the causal pathway leading to their impaired cardiac repair 
capacity.
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Of note, several cell populations have been suggested to promote cardiac 
neovascularization, including angiogenic EOCs, CD34+-cells, unselected bone marrow 
mononuclear cells or mesenchymal stem/progenitor cells.33 In the present study we have used 
angiogenic EOCs and CD34+-cells, because there are numerous reports suggesting that these 
cells can promote neovascularization in vivo.14-16, 18, 21, 24 Moreover, autologous angiogenic EOCs 
have been tested in a clinical trial in patients with ischemic cardiomyopathy,26  and an impaired 
effect on cardiac function has been observed,26 that was different from the effect observed in 
patients with an acute myocardial infarction using the same cell type.25 These findings raised the 
possibility that angiogenic EOCs from patients with ICM may have impaired pro-angiogenic 
effects.  Notably, the present study suggests that altered angiomiR expression of angiogenic 
EOCs from patients with CHF due to ICM is critical for their impaired capacity to promote 
cardiac neovascularization and function. 
Of note, the concept of how angiogenic EOCs or CD34+-cells may stimulate cardiac 
neovascularization has changed over the past years, contributing to modifications in 
classification and nomenclature of these cell populations.34-36 Whereas initially several cell 
populations derived after culture of bone-marrow- or circulating blood-derived  mononuclear 
cells were termed endothelial progenitor cells, later studies have suggested that these cell 
populations may rather act by paracrine mechanisms to stimulate neovascularization or 
endothelial repair than by differentiation into true endothelial cells, suggesting that the term 
endothelial progenitor cells was not adequate for most of these cell populations.34-36 Our own 
data suggest in fact that angiogenic EOCs are largely myeloid cells expressing markers of 
alternatively-activated M2-macrophages.  Of note, activation of monocytes and distinct 
macrophage populations (in particular M2-macrophages) has been shown to promote 
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angiogenesis, in part by releasing angiogenic factors.37, 38 In addition, culturing of human 
peripheral blood mononuclear cells (PB-MNCs) with endothelial growth medium has recently 
been suggested to stimulate the alternatively-activated, M2-like macrophage phenotype and up-
regulation of pro-angiogenic genes.39 Moreover, in line with this concept recent observations 
have suggested that endothelial cell co-culture promotes differentiation from several 
hematopoietic progenitors to macrophages and their polarization towards a pro-angiogenic M2-
phenotype.40
Furthermore, since angiogenic EOCs, as used in the present study, have to undergo an ex 
vivo culture period we have also examined expression of miR-126 and miR-130a in freshly 
isolated circulating CD34+-cells in order to exclude that the observation of a markedly reduced 
expression of these miRNAs would be limited to ex vivo cultured cells.  Indeed, miR-126 and 
miR-130a expression were markedly reduced in freshly isolated CD34+-cells derived from 
patients with CHF.
The profound down-regulation of angiomiRs miR-126 and miR-130a, as observed in the 
present study, is likely particularly prominent in circulating CD34+-cells and angiogenic EOCs 
from patients with CHF, as it was not detected in LV-tissue samples from patients with severe 
CHF examined in a recent study.41 Similarly, in a study that determined the miRNA expression 
profile in LV-tissue samples from non-failing and failing left ventricles due to DCM, no changes 
in the left ventricular expression of the above miRNAs have been reported.42 In a recent study, 
circulating miRNAs were determined in plasma from patients with CHF, and no significant 
changes were reported for miR-126 plasma levels.43
miR-126 has been suggested to represent an endothelial-lineage specific miRNA and 
regulates developmental neovascularization.7-9 Notably, miR-126 has been reported as the most 
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highly enriched miRNA in embryonic-body derived Flk1-positive vascular progenitor cells.7
Indeed, one may speculate that the common expression of miR-126 in endothelial cells and 
hematopoietic progenitor cells may relate to the observation that both hematopoietic and 
endothelial cells derive from a common precursor, i.e. the hemangioblast, reflecting the common 
early origin of hematopoietic and endothelial lineages.44, 45 Experimental studies in miR-126-/-
mice have suggested a critical role of miR-126 for cardiac neovascularization and survival post-
MI.8  The present study importantly extents these observations by suggesting a critical role of 
miR-126 for the cardiac neovascularization and repair capacity of angiogenic EOCs that is 
dysregulated in patients with CHF. Both studies support the concept that a reduced miR-126 
expression may critically impair the cardiac repair response.  Less is known about the role of 
miR-130a in angiogenesis; however, a recent in vitro study has suggested that miR-130a exerts 
important pro-angiogenic effects in endothelial cells, at least in part by inhibiting HOXA5.11
Notably, both miR-126 and miR-130a have been suggested to promote angiogenesis by 
directly repressing important inhibitors of angiogenic processes, including Sprouty-related EVH-
1 domain containing-1 (SPRED1) inhibited by miR-126 and HOXA5 repressed by miR-130a in 
endothelial cells.7, 8, 11  SPRED1 has been reported to suppress ERK activation and pro-
angiogenic signaling.7, 46  HOXA5 has been described to suppress angiogenic processes by 
several mechanisms, including down-regulation of pro-angiogenic proteins such as VEGFR2, 
Ephrin A1 and Hif1alpha, and by up-regulating anti-angiogenic genes such as Thrombospondin-
2 (TSP-2).47 In the present study, both SPRED1 and HOXA5 were up-regulated in angiogenic 
EOCs and circulating CD34+-cells from patients with CHF, further suggesting a functional 
relevance of the reduced angiomiR levels. Our SPRED1 and HOXA5-silencing experiments in 
angiogenic EOCs from patients with CHF demonstrated an improved pro-angiogenic capacity 
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after specific siRNA-knockdown, suggesting that these intracellular miRNA-targets are 
important regulators of the pro-angiogenic effects of angiogenic EOCs.  The exact mechanisms 
whereby angiogenic EOCs and CD34+-cells mediate their pro-angiogenic effects are not 
completely understood, however, paracrine mechanisms are likely involved, including release of 
exosomes containing several proteins, mRNAs and miRNAs.21, 48 Of note, SPRED1 has been 
shown to inhibit activation of ERK/mitogen-activated protein (MAP) kinase,7, 46, 49 that are also 
known regulators of VEGF.50 It is therefore conceivable that these intracellular miRNA-targets 
inhibit signaling pathways that regulate the paracrine activity of these cells.  The exact 
underlying molecular signaling mechanisms, however, will have to be characterized in future 
studies.
Furthermore, a recent study has suggested a dysregulation of miR-21 in angiogenic EOCs 
from patients with coronary artery disease,51 limiting their migratory capacity.  These 
observations support, together with the present findings, the potential dynamic regulation of 
miRNAs in angiogenic EOCs in cardiovascular pathophysiological conditions, and may also 
provide an explanation of why we did not completely restore cardiac repair capacity of 
angiogenic EOCs using miR-126-mimic treatment.  
Moreover, whereas both, anti-miR-126 and anti-miR-130a transfection of EOCs from HS 
reduced their capacity to promote cardiac neovascularization and improve cardiac function in 
vivo, only miR-126-mimic transfection significantly improved in vivo cardiac repair capacity of 
EOCs from patients with CHF.  Both, miR-126-mimic and miR-130a-mimic transfection 
improved the pro-angiogenic effects of EOCs from patients with CHF in vitro, however, in vivo
only miR-126-mimic transfection resulted in a significant improvement of their capacity to 
stimulate myocardial neovascularization and cardiac repair. 
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This observation raises the possibility that other mechanisms in addition to promotion of 
direct pro-angiogenic effects of angiogenic EOCs from patients with CHF after miR-126-mimic 
treatment may contribute to the observed in vivo effects.  Of note in this respect, a recent study 
has suggested that miR-126-release can increase SDF-1 expression and promote recruitment of 
endogenous progenitor cells to sites of injury in atherosclerotic mouse models.52  Therefore, it is 
conceivable that miR-126-mimic transfection may exert additional effects on angiogenic EOC-
function on top of direct pro-angiogenic properties.
Limitations of the present study 
In the present study we cannot exclude that there are also effects of the medication used by 
patients with CHF on the miRNA expression levels of angiogenic EOCs and CD34+-cells.  With 
respect to statin therapy, miR-126 and miR-130a expression levels of angiogenic EOCs from 
patients with CHF due to ICM did not differ significantly from angiogenic EOCs from patients 
with CHF due to DCM, although these patients were largely not on statin therapy.  However, 
future studies will need to characterize effects of different medications on miRNA levels in 
angiogenic EOCs and CD34+-cells.
In conclusion, the present study demonstrates a substantial loss of angiomiRs miR-126 
and miR-130a in angiogenic EOCs and circulating CD34+-cells from patients with CHF, and 
provides novel insights into their role for the impaired cardiac repair capacity of angiogenic 
EOCs from patients with CHF.  Anti-miR-126 transfection of angiogenic EOCs from HS impairs 
their capacity to improve myocardial neovascularization and cardiac function.  miR-126-mimic 
transfection improves the capacity of angiogenic EOCs from patients?with CHF to stimulate 
myocardial neovascularization and improves cardiac repair, suggesting a predominant role for 
this miRNA in regulating cardiac repair capacity of angiogenic EOCs. 
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Table 1. Characteristics of patients 
Healthy subjects Patients with CHF 
(ICM)
Patients with CHF 
(DCM)
n 35 45 15
Age (years) 56.7 ± 1.1 58.6 ± 1.0 57.9±2.4
Gender (m / f) 27/8 38 / 7 12/3
LV-Ejection fraction (%) 62.3 ± 2.7 31.4 ± 1.3 ‡ 30.2±3.5 ‡ 
LV-ESD (cm) 2.7±0.1 5.4±0.2 ‡ 5.5±0.3 ‡ 
LV-EDD (cm) 4.7±0.1 6.6±0.2 ‡ 6.4±0.2‡
NT-pro BNP (ng/l) 45 ± 6.0 2018 ± 533 ‡ 1577±550 ‡ 
LDL (mmol/l) 3.4 ±0.1 2.3 ±0.1‡ 3.3 ±0.2 
HDL (mmol/l) 1.7 ±0.1 1.1 ±0.1 ‡ 1.2 ±0.1 † 
Creatinine  (μM) 82.1 ± 2.5 113.5 ± 6.8 ‡ 108.8±12.2 † 
BMI (kg/m2) 23.7 ± 0.8 28.0 ± 0.7 ‡ 28.1±1.2 * 
NYHA class II/III/IV - 33/12/0 14/0/1
Medication
Beta-Blocker  43/45 15/15 
ACE inhibitor / ARBs 43/45 14/15
Diuretics  35/45 15/15 
Aldosterone antagonists 20/45 07/15
Statins 44/45 05/15
Aspirin  36/45 07/15
Vitamin K antagonists 10/45 07/15
CHF indicates chronic heart failure; ICM, ischemic cardiomyopathy; DCM, dilated cardiomyopathy; LV, left 
ventricular; ESD, end-systolic diameter; EDD, end-diastolic diameter; NT-pro BNP, N-terminal pro B-type 
natriuretic peptide; LDL, low-density lipoprotein; HDL, high-density lipoprotein; BMI, body mass index; NYHA, 
New York Heart Association; ACE, Angiotensin-converting enzyme; ARBs; Angiotensin receptor blockers. Values 
are mean ? SEM or number of patients. *, P<0.05 vs. Healthy subjects; †, P<0.01 vs. Healthy subjects; ‡, P<0.001 
vs. Healthy subjects. 
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Table 2. MRI and hemodynamic parameters in Sham or MI operated nude mice after treatment 
with placebo (PBS), angiogenic EOCs from healthy subjects or patients with CHF due to ICM .
Sham MI PBS MI EOCs Healthy
MI EOCs 
CHF (ICM) 
MRI     
LV Ejection Fraction, % 68.5±1.2 27.9±3.0† 42.0±3.9* 22.1±3.9 
LV ESV, μl 15.0±1.9 76.6±8.1† 55.4±7.5 80.8±12.1 
LV EDV, μl 44.8±4.7 104.2±7.6† 88.9±8.3 102.2±13.1 
Hemodynamic data     
LV dP/dtmax, mmHg/s 10412±1635 4738±516† 7401±331* 4915±546 
LV dP/dtmin, mmHg/s -9539±1101 -4689±489† -6322±430* -4218±420 
Heart rate, min-1 478±12 472±13 497±17 447±17 
LV indicates left ventricle; ESV, end-systolic volume; EDV, end-diastolic volume; MI, myocardial infarction; EOC, 
angiogenic early outgrowth cells; CHF, chronic heart failure; ICM, ischemic cardiomyopathy. n=8-16 per group. 
Values are mean ? SEM. *, P<0.05 vs. MI PBS; †, P<0.001 vs. Sham. 
Table 3. MRI and hemodynamic parameters in MI operated nude mice after treatment with 
angiogenic EOCs from healthy subjects, transfected with scrambled-miR, anti-miR-126 and anti-
miR-130a. 
MI  Healthy 
Scr-miR
MI Healthy 
Anti-miR-126 
MI Healthy 
Anti-miR-130a
MRI    
LV Ejection Fraction, % 44.43±4.9 28.3±2.8* 34.0±2.9
LV ESV, μl 49.5±9.5 82.8±9.8* 57.3±4.6
LV EDV, μl 88.1±14.2 113.4±10.3 86.0±3.8
Hemodynamic data    
dP/dtmax, mmHg/s 7743±594 5436±100* 5447±606* 
dP/dtmin, mmHg/s -6184±397 -5550±241 -4379±392* 
Heart rate, min-1 490±13 432±7* 419±15* 
LV indicates left ventricle; ESV, end-systolic volume; EDV, end-diastolic volume; MI, myocardial infarction; EOC, 
angiogenic early outgrowth cells; miR, microRNA; scr-miR, scrambled-microRNA.  n= 7-11 per group.  Values are 
mean ? SEM. *, P<0.05 vs. MI Healthy scr-miR 
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Table 4. MRI and hemodynamic parameters in MI operated nude mice after treatment with 
angiogenic EOCs from patients with CHF due to ICM, transfected with scrambled-miR, miR-
126-mimic and miR-130a-mimic. 
MI CHF (ICM)
Scr-miR
MI CHF (ICM) 
miR-126-mimic
MI CHF (ICM) 
miR-130a-mimic
MRI
LV Ejection Fraction, % 20.3±2.3 33.4±1.5* 29.1±6.4
LV ESV, μl 91.0±9.8 52.9±4.3* 76.0±17.3
LV EDV, μl 112.8±10.4 79.1±5.9 102.6±15.8
Hemodynamic data 
dP/dtmax, mmHg/s 5029±346 6605±355* 5717±547 
dP/dtmin, mmHg/s -4435±362 -5676±411 -5053±1105 
Heart rate, min-1 489±9.9 478±12.4 482±5.7 
LV indicates left ventricle; ESV, end-systolic volume; EDV, end-diastolic volume; MI, myocardial infarction; 
angiogenic EOC, early outgrowth cells; CHF, chronic heart failure; ICM, ischemic cardiomyopathy; miR, 
microRNA; scr-miR, scrambled-microRNA. n=5-8 per group. Values are mean ? SEM. *, P<0.05 vs. MI CHF 
(ICM) scr-miR. 
Figure Legends: 
Figure 1. A, Left ventricular ejection fraction (LV-EF), end-systolic volume (LV-ESV) and end-
diastolic volume (LV-EDV), measured by MRI, of nude mice post-MI at day 14 after injection 
of PBS or angiogenic EOCs from HS and patients with CHF due to ICM. n=8-16 per group. B, 
Representative short-axis views of a mid-ventricular slice for end-diastolic volumes from MRI 
measurements. Scale bar=200 um. C, LV-dPdtmax, measured with Millar catheter, of nude mice 
14 days post-MI and injection of PBS or angiogenic EOCs from HS and patients with CHF due 
to ICM. D, Capillary density (border zone between scar and remote myocardium) of mice after 
injection of PBS or angiogenic EOCs from healthy subjects and patients with CHF due to ICM 
post-MI at day 14. Above the graph photographs of capillary density are shown, stained for 
CD31 (brown); arrows are pointing to capillaries. E, Bioluminescence imaging of cell survival 
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on day 1 and 3 after transplantation of angiogenic EOCs from healthy subjects and patients with 
CHF due to ICM in the infarct border zone.  Background bioluminescence signal is denoted by 
the red line. Representative bioluminescence images are shown. n=5-6 for each time point. MI 
indicates myocardial infarction; EOCs, angiogenic early outgrowth cells; CHF, chronic heart 
failure; ICM, ischemic cardiomyopathy.  
Figure 2. Expression of miRNAs involved in angiogenesis in EOCs from patients with CHF due 
to ICM and HS. n=8. EOCs indicate angiogenic early outgrowth cells; CHF, chronic heart 
failure; ICM, ischemic cardiomyopathy; miR, microRNA. 
Figure 3. A, Effect of angiogenic EOCs from HS and patients with CHF due to ICM on HAEC-
mediated tube formation. On the right panel photographs of tube formation are shown. n=7-8. B, 
Effect of transfection with scrambled-miR, anti-miR-126 and anti-miR-130a on in vitro pro-
angiogenic effects of angiogenic EOCs from HS, as detected by tube formation. On the right 
panel photographs of tube formation are shown. n=4-6. C, SPRED1 expression – target of miR-
126 – and HOXA5 expression – target of miR-130a - on mRNA and protein level in angiogenic 
EOCs from HS and patients with CHF due to ICM. n=4-8. D and E, Effects on HAECs mediated 
tube formation after transfection of angiogenic EOCs from patients with CHF due to ICM with 
scrambled siRNA (scr-siRNA), siRNA for SPRED1 (siRNA-SPRED1) or HOXA5 (siRNA-
HOXA5). n=7-17. EOCs indicate angiogenic early outgrowth cells; CHF, chronic heart failure; 
ICM, ischemic cardiomyopathy; miR, microRNA. HAECs, human aortic endothelial cells. 
Figure 4. A, Left ventricular ejection fraction (LV-EF), end-systolic volume (LV-ESV) and end-
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diastolic volume (LV-EDV), measured by MRI, of nude mice post-MI at day 14 after injection 
of PBS or angiogenic EOCs from HS transfected with scrambled-miR, anti-miR-126 and anti-
miR-130a. n=7-11 per group. B, LV-dPdtmax, measured with Millar catheter, of nude mice after 
injection of angiogenic EOCs from HS transfected with scrambled-miR, anti-miR-126 and anti-
miR-130a post-MI at day 14. C, Capillary density (border zone between scar and remote 
myocardium) of mice after injection of angiogenic EOCs from HS transfected with scrambled-
miR, anti-miR-126 and anti-miR-130a post-MI at day 14. Above bar graphs: photographs of 
capillary density, stained for CD31 (brown), the arrows are pointing to capillaries. D, 
Bioluminescence imaging of cell survival on day 1 and 3 after transplantation of angiogenic 
EOCs from HS transfected with scrambled-miR and anti-miR-126. Background bioluminescence 
signal is denoted by the red line. n=5. EOCs indicate angiogenic early outgrowth cells; MI, 
myocardial infarction; miR, microRNA. 
Figure 5. A, Left ventricular ejection fraction (LV-EF), end-systolic volume (LV-ESV) and end-
diastolic volume (LV-EDV), measured by MRI, of nude mice after transplantation of angiogenic 
EOCs from patients with CHF due to ICM transfected with scrambled-miR, miR-126-mimic and 
miR-130a-mimic post myocardial infarction at day 14. n=5-8 per group. B, LV-dPdtmax, 
measured with Millar catheter, of mice after injection of angiogenic EOCs from patients with 
CHF due to ICM transfected with scrambled-miR, miR-126-mimic and miR-130a-mimic post-
MI at day 14. C, Capillary density (infarct border zone) of mice after injection of angiogenic 
EOCs from patients with CHF due to ICM transfected with scrambled-miR, miR-126-mimic and 
miR-130a-mimic post-MI at day 14. Above bar graphs: photographs of capillary density, stained 
for CD31 (brown), the arrows are pointing to capillaries. EOCs indicate angiogenic early 
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outgrowth cells; CHF, chronic heart failure; ICM, ischemic cardiomyopathy; MI, myocardial 
infarction; miR, microRNA. 
Figure 6. A, Expression of miR-126 and miR-130a and their targets - SPRED1 and HOXA5 - in 
circulating CD34+-cells from HS and patients with CHF due to ICM. B, Analysis of the effect of 
CD34+-cells from HS and patients with CHF due to ICM on HAEC-mediated tube formation in 
matrigel. On the right panel photographs of tube formation are presented. n=4-8. CD34+
indicates circulating CD34+-cells; CHF, chronic heart failure; ICM, ischemic cardiomyopathy; 
miR, microRNA; HAECs, human aortic endothelial cells. 
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SUPPLEMENTAL METHODS 
Isolation and Cultivation of Angiogenic EOCs and CD34+ Progenitor Cells: Angiogenic 
EOCs were isolated and cultured as described in detail previously.1-4 In brief, peripheral 
blood mononuclear cells were isolated by density gradient centrifugation with LSM 1077 
(PAA Laboratories), and 3.8x107 cells were cultured on fibronectin-coated 100 mm dishes in 
endothelial cell basal medium-2 supplemented with endothelial growth medium. Single quots 
were used as indicated by the manufacturer, 10 % of fetal bovine serum (FBS) was added. 
After 4 day culture, nonadherent cells were removed. Remaining cells were trypsinized and 
used for the in vivo and in vitro analyses.  
Of note, the classification schemes and nomenclature of the different cell populations with 
pro-angiogenic properties varies in the literature and has been substantially modified by 
several groups over the past years.5-7 Whereas initially several different cell populations 
derived after culture of bone-marrow- or circulating blood-derived  mononuclear cells have 
been termed endothelial progenitor cells, later studies have suggested that most of these cell 
populations may act to stimulate neovascularization or endothelial repair by paracrine 
mechanisms rather than by differentiation towards true endothelial cells, suggesting that the 
term endothelial progenitor cells was not adaequat for most of these cell populations.7, 8	  We 
have therefore used the term angiogenic early outgrowth cells (EOCs) rather than endothelial 
progenitor cells in the present study. We have previously reported that these angiogenic 
EOCs are characterized by cellular uptake of 1,1-dioctadecyl-3,3,3,3-
tetramethylindocarbocyanine-labeled acetylated LDL (acLDL-DiI) and binding of FITC-
labeled Ulex europaeus agglutinin-1 lectin (UEA-1).1-3, 9 Additionally, angiogenic EOCs 
from HS and patients with CHF were characterized using flow cytometry (Supplemental 
Figure 1 and Supplemental Tables 1-3). Angiogenic EOCs from HS were transfected with 
scrambled-miR, anti-miR-126 or anti-miR-130a and angiogenic EOCs from patients with 
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CHF were transfected with scrambled-miR, miR-126-mimic and miR-130a-mimic. 
Thereafter, the cell surface phenotype of angiogenic EOCs was assessed using the following 
antibodies: CD14, CD86, CD163, CD206, CD3, CD4, CD8, CD19, CD45, CD34, CD133 
and KDR (all except CD34 and CD133 (Miltenyi Biotec) from BioLegend) at day 3 after 
transfection.  No changes of cell surface markers were observed after transfection of 
angiogenic EOCs with miR-126 and miR-130a, indicating that miR-126 and miR-130a 
expression levels do not affect these cell surface markers (Supplemental Figure 1 and 
Supplemental Tables 2-3).  
Importantly, we have previously clearly demonstrated that angiogenic EOCs, as examined in 
the present study, can promote endothelial repair after vascular injury in vivo, but the 
transplanted angiogenic EOCs were located adjacent to the endothelial cell layer rather than 
becoming endothelial cells, therefore likely acting by paracrine mechanisms.1, 4  
For isolation of CD 34+ cells, mononuclear cells were magnetically labeled with CD34-beads 
and separated in a MACS-column placed in a MACS-separator according to the 
manufacturer`s instructions (Miltenyi-Biotec).  
 
Animals, Myocardial Infarction and Cell Transplantation: Animal experiments were 
approved by the local committee. Male NMRI nu/nu mice, aged 10-16 weeks were used for 
transplantation of human angiogenic EOCs. Mice were housed under specific pathogen-
reduced conditions receiving autoclaved chow and water ad libitum. Myocardial infarction 
(MI) was induced by permanent ligation of the left anterior descending coronary artery, as 
described in detail previously.2, 10-12 An injection anesthesia (Medetomidin – 20 µg/kg 
/Climazolam – 0.2 mg/kg /Fentanyl – 2 µg/kg) was used for the operation. Ten minutes post 
MI, 5x105 human angiogenic EOCs or placebo (i.e. the same volume of PBS buffer) were 
injected intramyocardially into the infarct border zone at 4 sites using a 30G needle. 
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Magnetic resonance imaging (MRI), hemodynamic measurements (Millar catheter), 
histomorphometric analysis and immunohistochemistry were performed 14 days after MI. 
For in vivo bioluminescence imaging, 1x106 human Ad-Luc EOCs, anti-miR-126 transfected 
Ad-Luc EOCs or Ad-GFP EOCs as control were injected post MI.  
 
Cardiac Magnetic Resonance Imaging: MRI experiments were performed on a 9.4 T small 
animal MRI system (Bruker BioSpin MRI, Ettlingen, Germany) equipped with a gradient 
system capable of 400 mT/m in a minimum rise time of 80 µs. Animals were anesthetized 
using 1 to 2% isoflurane in an oxygen/air (80/20 %) mixture. For MR signal transmission and 
reception a circular polarized birdcage resonator with an inner diameter of 21 mm was used. 
The self gated cardiac imaging method IntraGate (ParaVision 5.0, Bruker BioSpin, Ettlingen, 
Germany) was applied to acquire long-axis, short-axis and four-chamber scout views of the 
heart which were subsequently used as a basis for planning of the cine FLASH sequence. 
Contiguous 1-mm slices in short axis orientation covering the entire long axis of the heart 
were acquired. Remaining sequence parameters were: field of view (FOV) = 2.50 cm x 2.50 
cm, matrix size = 256 x 256, flip angle = 10°, echo / repetition time (TE / TR) = 1.812 / 
57.682 ms resulting in a total scan time of 24 min and 26 sec. In post processing acquired 
MR image data was assigned to 10 cardiac phases and the end-expiratory motion state 
according to the self-gating signal. MRI images were analyzed to determine end-diastolic and 
end-systolic volumes using BioMap 4.2 A (M. Rausch, Novartis, Basel, Switzerland) and 
subsequently LV ejection fractions were calculated from the obtained values. 
 
Hemodynamic Measurements of Cardiac Function: Hemodynamic measurements were 
performed using a 1.4F micromanometer conductance catheter (Millar Instruments) as 
described previously.11 In brief, animals were anesthetized with isoflurane (1-2%), 
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mechanically ventilated and the catheter was inserted in the LV cavity via the right carotid 
artery. For obtaining and analyzing the hemodynamic data the software PVAN 3.6 (Millar) 
was used. 
 
Histology: Two weeks post myocardial infarction hearts were arrested in diastole with 
potassium chloride and left ventricles (LV) were harvested as described previously.2, 10, 11 LV 
tissue slices were embedded in paraffin, cut into 4-µm sections and immunohistochemistry 
for CD31 (rabbit polyclonal CD31 Antibody, Abcam, Cambridge, MA, USA) was performed 
by using a BondMax immunostaining machine (Leica) as instructed by the manufacturer 
including a refine DAB-kit to determine capillary density. Capillaries in the infarct border 
zone of LV were counted in 6 high power fields (400x magnification; 200x200 µm) by an 
investigator unaware of the treatment group and results were expressed as capillaries per 
mm2.  
For EOC incorporation, angiogenic EOCs were labeled with vybrant Dil (Invitrogen) 
according to the manufacturer's protocol, washed three times with growth medium and 
transplanted into the infarct border zone. After 2 days, endothelial cells were labeled with 75 
ul of Fluorescein labeled GSL I – isolectin B4 (Vector Laboratories) via tail vein injection. 
Hearts were harvested after 45 min. Frozen tissue sections (5 um) were mounted in 
Vectashield mounting media with 4-,6-diamidino-2-phenylindole (DAPI) (Vector 
Laboratories) and examined by confocal microscopy (SP5 Leica Microsystem, Germany). 
 
Transfection of Angiogenic EOCs: For viral transfection of angiogenic EOCs, peripheral 
blood mononuclear cells were isolated and cultured on fibronectin-coated 6-well plates. At 
day 3, non-adherent cells were removed and adherent cells were transfected (multiplicity of 
infection 400) with an adenovirus carrying luciferase (Ad-Luc EOCs) or GFP (Ad-GFP 
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EOCs) (ViraQuest, Inc., IA, USA). After 24 hours, virus containing supernatant was removed 
and, after washing with PBS, transfected angiogenic EOCs were kept in EGM-2 containing 
10% FBS till further use. For transfection efficiency, Ad-GFP EOCs were analyzed by 
FACS. Transfection efficiency was 81.1±3.7%.  
 
Bioluminescence imaging: Cardiac bioluminescence imaging was performed using the 
Xenogen IVIS 200 system (Caliper Life Sciences). Mice were anaesthetized with 2% 
isoflurane. 29 minutes after intraperitoneal injection of luciferin (200 mg/kg), images were 
acquired for 5 minutes on day 1 and 3 post-MI and transplantation of 1x106 human Ad-Luc 
EOCs from HS and patients with CHF due to ICM, anti-miR-126 transfected Ad-Luc EOCs 
from HS or Ad-GFP EOCs (control). Imaging signals were quantified using a fixed region of 
interest (ROI) in photons/sec/cm2/sr.  In addition, bioluminescence signals of freshly 
explanted organs (heart, lung, liver and spleen) were determined on day 3 after intra-
myocardial transplantation. 
 
RNA Isolation, microRNA Array and Real Time PCR Analysis: Total RNA was 
extracted from angiogenic EOCs and CD34+ cells using QIAzol Reagent (Qiagen) and 
miRNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions.   
For miRNA-profiling the miRCURYTM LNA Array from Exiqon (Version 10.0), a 
hybridization-based array, was used.  After hybridization the microarray slides were stored in 
ozone free environment (ozone level below 2.0 ppb). The miRCURY™ LNA array 
microarray slides were scanned using the Agilent G2565BA Microarray Scanner System 
(Agilent Technologies, Inc., USA) and image analysis was carried out using the ImaGene 7.0 
software (BioDiscovery, Inc., USA). The quantified signals were normalized using the global 
Lowess (LOcally WEighted Scatterplot Smoothing) regression algorithm.  In this array, the 
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expression of each miRNA is measured by hybridization using four probes placed across the 
slide and each miRNA is coded by green fluorescence (Hy3). A mixture of all samples is 
used as control or common reference and is coded by red fluorescence (Hy5). After 
hybridization, a Hy3 signal intensity and Hy5 signal intensity of each of the four probes was 
determined. The median of the four Hy3/Hy5 ratios was calculated and subsequently log2 
transformed.  In the Supplementary Table 4A the normalized Hy3/Hy5 ratios (log2 
transformed) from all 4 samples (Healthy 1 to 4) and the mean values with the standard 
deviation of miRNAs, which were found to be expressed in angiogenic EOCs are shown. 
AngiomiR expression in EOCs and CD34+ cells from patients with ICM or DCM and HS 
was compared by using real-time PCR analysis. Firstly c-DNA synthesis was performed with 
5 ng of total RNA in a final volume of 10 µl, according to the manufacturer’s instruction 
(miRCURY LNA™ first-strand cDNA kit, Exiqon, Denmark). Real-time PCR was 
performed with a MX3000P PCR cycler (Stratagene, Amsterdam, Netherlands). All 
experiments were performed in at least quadruplicates using the miRCURY LNA™ 
microRNA PCR system (Exiqon, Denmark). Each reaction (25 µl) contained 0.4 µl cDNA, 
10 pmol of each primer, 0.25 µl of internal reference dye, and 12.5 µl of SYBR Green master 
mix. The amplification program consisted of 1 cycle at 95 °C for 10 min, followed by 40 
cycles with a denaturing phase at 95 °C for 20 s and an annealing phase at 60 °C for 1 min. 
Data were normalized to results obtained with primers specific for U6. 
 
Anti-miR and miR-mimic Transfection: Angiogenic EOCs were transfected with 25 pmol 
of scrambled-miR, anti-miR-126 or anti-miR-130a (Exiqon, Denmark) or 25 pmol of 
scrambled-miR, miR-126-mimic or miR-130a-mimic (Ambion) in a total volume of 75 µl in 
DMEM. The conditions for electroporation were the following: 200 V, 1 pulse and 10 µs 
(BTX, ECM 830, MA, USA). Cells were incubated for 12 hours at 37°C and 5% CO2. The 
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sequences of the used anti-miRs and miR-mimics are listed in the supplemental Table 2 and 
3. Transfection efficiency was tested by electroporation of angiogenic EOCs with FITC-
labeled scrambled-miR and was > 80 %.  
 
Tube Formation Assay: To assess the pro-angiogenic activity of EOCs and CD34+ cells, 
tube formation capacity after co-incubation of 2x103 angiogenic EOCs and 8x103 HAECs 
was examined in 50 µl of Matrigel (BD, growth factor reduced) in EGM 2 medium in 1 well 
of a 96 well plate for 6 hours. HAECs alone served as positive control, angiogenic EOCs and 
CD34+ cells alone were used as negative control. The number of completely formed tubes 
was counted in 5 high power fields (40x magnification) by an investigator unaware of the 
treatment group. All results were normalized to the positive control. 
 
Aortic Ring Assay: C57BL/6 mice were euthanized and thoracic aortas were harvested. 
Fibroadipose tissue was carefully removed. Aortas were cut into 1mm pieces. Aortic rings 
were embedded in Matrigel (BD, growth factor reduced) and incubated with EBM-2 
containing 2% FBS (control), anti-miR-126, anti-miR-130a or scrambled-miR transfected 
angiogenic EOCs in EBM-2 containing 2% FBS. Endothelial sprouting was analyzed by 
visual counting at day 6 by an investigator unaware of the treatment group. All results were 
normalized to the control. 
Real Time PCR Analysis of SPRED1 and HOXA5: Conversion of total RNA to cDNA 
was performed using Moloney murine leukemia virus reverse transcriptase and random 
hexamer primers (Amersham Biosciences, Piscataway, NJ) in a final volume of 33 µl using 
0,4 µg of RNA. Real-time PCR was performed using a MX3000P PCR cycler (Stratagene, 
Amsterdam, Netherlands). All experiments were performed in at least quadruplicate using the 
SYBR Green JumpStart kit (Sigma). Each reaction (25 µl) contained 2 µl cDNA, 10 pmol of 
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each primer, 0.25 µl of internal reference dye, and 12.5 µl of JumpStart Taq ReadyMix 
(containing buffer, dNTPs, stabilizers, SYBR Green, Taq polymerase and JumpStart Taq 
antibody). The amplification program consisted of 1 cycle at 95 °C for 10 min, followed by 
40 cycles with a denaturing phase at 95 °C for 30 s, an annealing phase at 60 °C for 1 min, 
and an elongation phase at 72 °C for 1 min. A melting curve analysis was performed after 
amplification to verify the accuracy of the amplicon, and PCR products were analyzed on an 
ethidium bromide stained 1% agarose gel. Data were normalized to results obtained with 
primers specific for human L28, TBP or GAPDH. The sequences of the used primers are 
listed in the supplemental Table 1. 
Western Blot Analysis: Expression of SPRED1 and HOXA5 was analyzed by western 
blotting as described previously11, using the following antibodies: SPRED1 antibody (C-
term, Abgent; San Diego, CA, USA), HOXA5 antibody (Abcam, Cambridge, MA, USA), a 
horseradish peroxidase conjugated secondary anti-mouse or an anti-rabbit antibody 
(Amersham Biosciences). Equal protein loading was verified by reprobing the membrane 
with a mouse anti-GAPDH antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
siRNA Silencing of SPRED1 and HOXA5: Angiogenic EOCs were harvested for 
electroporation and 1x106 angiogenic EOCs were transfected with 33 nmol of scrambled 
siRNA, SPRED1 siRNA (SantaCruz) or HOXA5 siRNA (SantaCruz) in a total volume of 
300µl. The conditions for electroporation were the following: 250V, 1 pulse and 125 µFD 
(BioRad, Gene Pulser). Cells were incubated for 48 hours at 37°C and 5% CO2, washed and 
subsequently used to perform in vitro tube formation assay. 
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SUPPLEMENTAL FIGURES 
Supplemental Figure 1 
 
Supplemental Figure 1: A, Characterization of angiogenic EOCs by flow cytometry. Using 
forward and side-scatter characteristics, a larger population with higher granularity (P1) and a 
smaller population with low granularity (P2) were identified. Further characterization 
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revealed that the P1 gate contains largely cells with a myeloid phenotype (positive for CD14 
and/or macrophage markers CD86, 163 and 206) and that the P2 gate contained largely cells 
with a lymphoid marker expression (CD3, CD19).  For characterization of P1, isotype control 
is depicted in grey and a representative stained sample is depicted in blue. For 
characterization of lymphoid cells in the P2 gate, dot plots were used to first identify CD3-
CD19+ B-lymphocytes as well as CD3+CD19- T-lymphocytes (two left panels). CD19-
CD3+ lymphocytes were then further characterized with regard to their expression of CD4 or 
CD8 (two right panels). Isotype control and stained sample are shown as separate plots.  
B, Putative progenitor cells within angiogenic EOCs were quantified using a modified 
ISHAGE-based strategy. Cells with low side scatter and positivity for either CD34 or CD133 
were identified (left panel). Among those, cells with low CD45 expression were identified 
(CD45dim, middle panel). CD34+ CD45dim SSClo as well as CD133+ CD45dim SSClo 
cells were further characterized with regard to their KDR expression (right panel). 
EOCs indicate angiogenic early outgrowth cells; CD, cluster of differentiation; KDR, kinase 
insert domain protein receptor. 
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Supplemental Figure 2 
 
Supplemental Figure 2. Viral transfection of angiogenic EOCs. A, Representative 
photomicrographs of angiogenic EOCs transfected with an adenovirus carrying GFP (Ad-
GFP EOCs), detected by fluorescence microscopy (left panel) and flow cytometric histogram 
of Ad-GFP EOCs (red filled histogram) (right panel). B, Correlation of cell count of 
angiogenic EOCs transfected with an adenovirus carrying luciferase and bioluminescence 
signal in vitro. C, Bioluminescence signal of explanted organs on day 3 after myocardial 
infarction and transplantation of angiogenic EOCs. On the right hand side representative 
bioluminescence imaging of explanted organs are shown. n=4-5. EOC indicates angiogenic 
early outgrowth cells; HS, healthy subject; CHF, chronic heart failure; ICM, ischemic 
cardiomyopathy 
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Supplemental Figure 3 
 
 
 
Supplemental Figure 3: Localization and detection of transplanted, vybrant Dil-labeled 
angiogenic EOCs (red) after myocardial infarction (48h post myocardial infarction). Vessels 
are stained with Isolectin B4 (green), Nuclei with DAPI (blue). A, Angiogenic EOCs were 
detected in the infarct border zone; arrows are pointing to the nuclei of angiogenic EOCs. 
Scale bar=20 um. B, Higher magnification of an EOC detected in close vicinity to an 
endothelial cell, arrow is pointing to the nucleus of the EOC, scale bar=5um. EOC indicates 
angiogenic early outgrowth cell; Lectin, Isolectin B4.  
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Supplemental Figure 4 
  
 
 
Supplemental Figure 4: Effect of angiogenic EOCs from healthy subjects on HAECs 
mediated tube formation after transfection with scrambled-miR, miR-126-mimic and miR-
130a-mimic. n=8. EOC indicates angiogenic early outgrowth cells; HAECs, human aortic 
endothelial cells. 
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Supplemental Figure 5 
Supplemental Figure 5: miR-126 and miR-130a expression levels in angiogenic EOCs after 
transfection with (A) miR-scrambled, anti-miR-126 or miR-126-mimic and (B) miR-
scrambled, anti-miR-130a or miR-130a-mimic. n=4-12. EOCs indicate angiogenic early 
outgrowth cells; miR, microRNA. 
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Supplemental Figure 6 
 
Supplemental Figure 6: A, Expression of miR-126 and miR-130a and their targets - 
SPRED1 and HOXA5 - in angiogenic EOCs from healthy subjects and patients with CHF 
due to DCM. n=5-8. B, Analysis of the effect of angiogenic EOCs from healthy subjects and 
patients with CHF due to DCM on HAECs mediated tube formation in matrigel. On the right 
panel photographs of tube formation are presented. n=7-8. EOCs indicate angiogenic early 
outgrowth cells; CHF, chronic heart failure; DCM, dilated cardiomyopathy; miR, microRNA. 
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Supplemental Figure 7 
 
Supplemental Figure 7: A, Expression of miR-126 and miR-130a and their targets - 
SPRED1 and HOXA5 - in CD34+ cells from healthy subjects and patients with CHF due to 
DCM. B, Analysis of the effect of CD34+ cells from healthy subjects and patients with CHF 
due to DCM on HAECs mediated tube formation in matrigel. On the right panel photographs 
of tube formation are presented. n=4-8. CD34+ indicates circulating CD34+ cells; CHF, 
chronic heart failure; DCM, dilated cardiomyopathy; miR, microRNA. 
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Supplemental Figure 8 
 
 
Supplemental Figure 8: Expression of EGFL7 on mRNA level in angiogenic EOCs from 
healthy subjects and patients with CHF due to ICM and DCM. n=6-7.  EGF-like domain 7 
(EGFL7) is the gene encoding miR-126.13 EOC indicates angiogenic early outgrowth cells; 
CHF, chronic heart failure; ICM, ischemic cardiomyopathy; DCM, dilated cardiomyopathy; 
EGFL7, EGF-like domain 7. 
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Supplemental Figure 9 
 
 
Supplemental Figure 9: Comparison of miR-126 and miR-130a and their targets in 
angiogenic EOCs from patients with CHF due to ICM and angiogenic EOCs from patients 
with CHF due to DCM. MiR-126 (A) and miR-130a (B) expression levels in angiogenic 
EOCs from patients with CHF due to ICM as compared to angiogenic EOCs from patients 
with CHF due to DCM. SPRED1 expression (C) - target of miR-126 - and HOXA5 
expression (D) - target of miR-130a - in angiogenic EOCs from patients with CHF due to 
ICM and DCM. n=5-8. EOC indicates angiogenic early outgrowth cells; CHF, chronic heart 
failure; ICM, ischemic cardiomyopathy; DCM, dilated cardiomyopathy; miR, microRNA. 
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SUPPLEMENTAL TABLES 
Supplemental Table 1. Comparison of cell surface phenotype of angiogenic EOCs from 
HS and angiogenic EOCs from patients with CHF using flow cytometry 
Antigenic marker EOCs-HS EOCs-CHF 
P1 gate  (% positive cells)    
CD14+ 90.0±5.8 99.1±0.5 
CD86+ 58.6±7.0 69.1±6.1 
CD163+ 76.2±7.4 76.1±3.5 
CD206+ 82.7±5.4 78.0±5.3 
   
P1&P2 gate (% positive cells):    
CD34+CD45dim 1.1±0.3 0.25±0.1* 
CD34+CD45dimKDR+ 0.03±0.01 0.01±0.00 
CD133+CD45dim 0.09±0.04 0.09±0.06 
CD133+CD45dimKDR+ 0.06±0.03 0.07±0.05 
CD45+ 92.7±1.9 94.8±2.3 
   
P2 gate (% positive cells):    
CD3+CD19- 61.3±7.1 65.9±7.1 
CD4+CD3+CD8-CD19- 31.6±5.4 29.5±4.8 
CD8+CD3+CD4-CD19- 19.2±3.0 28.5±6.9 
CD19+CD3- 3.4±1.4 6.1±2.6 
 
HS indicates healthy subjects; CHF, chronic heart failure; EOCs, angiogenic early outgrowth 
cells (with scrambled-miR transfection). For the gating strategy (P1 and P2 gates) please see 
supplemental figure 1.  n=5-6 per group. Values are mean ± SEM. *, P<0.05 vs. EOCs-HS. 
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Supplemental Table 2. Comparison of cell surface phenotype of angiogenic EOCs from 
HS transfected with miR-scrambled, anti-miR-126 or anti-miR-130a using flow 
cytometry 
Antigenic marker 
EOCs-HS 
scrambled-
miRNA  
EOCs-HS 
anti-miR-126 
EOCs-HS 
anti-miR-130a 
P1 gate  (% positive cells)       
CD14+ 90.0±5.8 93.3±3.5 90.5±4.2 
CD86+ 58.6±7.0 59.2±9.0 54.7±6.6 
CD163+ 76.2±7.4 76.7±6.7 72.0±7.7 
CD206+ 82.7±5.4 83.2±4.0 78.6±5.8 
    
P1&P2 gate (% positive cells):       
CD34+CD45dim 1.1±0.3 1.1±0.3 1.0±0.3 
CD34+CD45dimKDR+ 0.03±0.01 0.02±0.01 0.03±0.01 
CD133+CD45dim 0.09±0.04 0.07±0.03 0.06±0.02 
CD133+CD45dimKDR+ 0.06±0.03 0.05±0.02 0.04±0.02 
CD45+ 92.7±1.9 92.9±1.3 92.9±1.5 
    
P2 gate (% positive cells):       
CD3+CD19- 61.3±7.1 60.1±7.0 60.4±7.4 
CD4+CD3+CD8-CD19- 31.6±5.4 31.8±5.3 32.4±5.6 
CD8+CD3+CD4-CD19- 19.2±3.0 18.4±3.0 17.8±2.6 
CD19+CD3- 3.4±1.4 4.2±1.8 3.8±1.6 
 
EOCs indicate angiogenic early outgrowth cells; HS, healthy subjects; miR, microRNA. For 
gating strategy (P1 and P2 gates) please refer to supplemental figure 1. n=5-6 per group. 
Values are mean ± SEM. P = n.s. for all comparisons. 
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Supplemental Table 3. Comparison of cell surface phenotype of angiogenic EOCs from 
patients with CHF transfected with miR-scrambled, miR-126-mimic or miR-130a-
mimic using flow cytometry 
Antigenic marker 
EOCs-CHF 
scrambled-
miRNA 
EOCs-CHF 
miR-126-mimic  
EOCs-CHF 
miR-130a-mimic  
P1 gate  (% positive cells)       
CD14+ 99.1±0.5 99.2±0.3 99.3±0.3 
CD86+ 69.1±6.1 73.6±5.3 70.0±6.6 
CD163+ 76.1±3.5 76.3±4.3 75.8±4.1 
CD206+ 78.0±5.3 80.1±4.5 74.1±9.1 
    
P1&P2 gate (% positive cells):       
CD34+CD45dim 0.25±0.08 0.25±0.07 0.27±0.09 
CD34+CD45dimKDR+ 0.01±0.00 0.01±0.00 0.01±0.00 
CD133+CD45dim 0.09±0.06 0.06±0.04 0.06±0.05 
CD133+CD45dimKDR+ 0.07±0.05 0.05±0.03 0.05±0.04 
CD45+ 94.8±2.3 94.8±2.4 93.8±2.7 
    
P2 gate (% positive cells):       
CD3+CD19- 65.9±7.1 66.1±7.6 66.1±7.6 
CD4+CD3+CD8-CD19- 29.5±4.8 31.0±4.0 29.8±4.7 
CD8+CD3+CD4-CD19- 28.5±6.9 27.2±6.8 28.0±6.6 
CD19+CD3- 6.1±2.6 6.0±2.5 6.6±3.1 
 
EOCs indicate angiogenic early outgrowth cells; CHF, chronic heart failure; miR, 
microRNA. For gating strategy (P1 and P2 gates) please refer to supplemental figure 1. n=5-6 
per group. Values are mean ± SEM. P = n.s. for all comparisons. 
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Supplemental Table 4. MicroRNA Array Profiling 
Total RNA from sample and reference were labeled with Hy3™ and Hy5™ fluorescent label, 
respectively. The Hy3™-labelled samples and a Hy5™-labelled reference RNA sample were 
mixed pair-wise and hybridized to the miRCURY™ LNA array. After hybridization the 
microarray slides were scanned and the image analysis was carried out. 294 out of 757 
miRNAs were found to be expressed in angiogenic EOCs. A, Normalized Hy3/Hy5 ratios 
(log2 transformed) from angiogenic EOCs from 4 healthy subjects. B, Median Hy3 signal 
from miRNAs and median Hy5 signal from reference of angiogenic EOCs from 4 healthy 
subjects. 
 
A, Normalized Hy3/Hy5 ratios (log2 transformed) 	  
  Healthy 1 Healthy  2 Healthy  3 Healthy 4 
Mean 
values SD 
hsa-let-7f NA 1.74 4.08 NA 2.9 1.9 
hsa-miR-32 NA 2.16 4.46 0.82 2.48 1.84 
hsa-miR-16 1.30 2.51 3.32 1.20 2.08 1.02 
hsa-miR-20b NA 1.99 3.68 0.47 2.05 1.60 
hsa-miR-335 NA 0.50 3.32 NA 1.91 1.99 
hsa-miR-301a 0.36 1.38 3.28 NA 1.68 1.48 
hsa-miR-30e* 0.91 1.73 3.26 0.77 1.67 1.14 
hsa-miR-142-3p 0.91 2.07 2.22 1.28 1.62 0.63 
hsa-miR-27b 0.65 1.89 3.45 0.46 1.61 1.38 
hsa-miR-30e 0.81 1.77 2.94 0.94 1.61 0.98 
hsa-miR-374a 0.89 1.81 2.87 0.74 1.58 0.98 
hsa-miR-140-5p 0.76 1.84 3.03 0.58 1.55 1.13 
hsa-miR-19a 0.82 1.80 2.62 0.81 1.51 0.87 
hsa-let-7a 0.62 2.01 2.98 0.42 1.51 1.21 
hsa-miR-126 0.04 -0.11 5.17 0.77 1.47 2.50 
hsa-miR-130a 0.28 0.29 4.19 0.65 1.35 1.90 
hsa-miR-17 0.56 1.55 2.60 0.60 1.33 0.96 
hsa-miR-106a 0.57 1.59 2.54 0.61 1.33 0.94 
hsa-miR-98 NA 1.09 2.50 0.37 1.32 1.09 
hsa-miR-29b 0.60 1.70 2.11 0.80 1.30 0.72 
hsa-miR-18b 0.69 1.36 2.62 0.33 1.25 1.01 
hsa-let-7g 0.24 1.60 2.73 0.41 1.25 1.16 
hsa-miR-26b 0.52 1.53 2.01 0.81 1.22 0.68 
hsa-miR-363* 0.99 1.07 1.82 0.85 1.18 0.43 
hsa-miR-23b 0.74 1.23 2.30 0.44 1.18 0.81 
hsa-miR-15a 0.82 1.49 1.95 0.44 1.17 0.68 
hsa-miR-101 0.56 1.51 1.82 0.77 1.16 0.60 
hsa-miR-29a* 0.69 1.42 1.93 0.58 1.15 0.64 
hsa-miR-668 0.58 1.29 2.30 0.37 1.13 0.87 
hsa-miR-15b 0.47 1.28 2.22 0.51 1.12 0.82 
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hsa-miR-154 0.55 1.23 2.38 0.32 1.12 0.93 
hsa-miR-18a 0.55 1.36 2.41 0.11 1.11 1.01 
hsa-miR-374b 0.44 1.26 2.44 0.27 1.10 0.99 
hsa-miR-20a 0.39 1.33 2.20 0.45 1.09 0.85 
hsa-miR-616* 0.92 NA 1.24 1.02 1.06 0.16 
hsa-miR-768-5p 0.14 1.31 2.19 0.57 1.06 0.90 
hsa-miR-33a 0.20 1.08 2.19 0.74 1.05 0.84 
hsa-miR-105 0.73 1.53 1.80 0.13 1.05 0.76 
hsa-miR-28-5p 0.35 1.00 2.58 0.26 1.05 1.07 
hsa-miR-148a NA 0.57 1.50 NA 1.03 0.66 
hsa-miR-7 0.56 0.97 1.88 0.59 1.00 0.61 
hsa-miR-195 0.36 0.98 2.34 0.30 1.00 0.95 
hsa-miR-424 0.53 1.22 1.74 0.43 0.98 0.61 
hsa-miR-342-3p 0.23 1.25 1.77 0.62 0.97 0.68 
hsa-miR-483-3p 1.20 0.80 0.94 0.91 0.96 0.17 
hsa-miR-223 0.73 1.14 1.82 0.07 0.94 0.73 
hsa-miR-22* 0.47 1.10 1.90 0.17 0.91 0.77 
hsa-miR-199a-5p 0.30 -0.30 2.79 0.85 0.91 1.34 
hsa-miR-107 0.43 0.99 1.99 0.22 0.91 0.79 
hsa-miR-150* NA 0.60 1.21 NA 0.90 0.44 
hsa-miR-194 0.40 0.92 1.84 0.45 0.90 0.67 
hsa-miR-21 0.99 1.55 0.66 0.40 0.90 0.49 
hsa-miR-30b 0.24 1.06 1.98 0.26 0.89 0.82 
hsa-miR-338-3p 0.99 1.85 1.37 -0.68 0.88 1.10 
hsa-let-7i 0.41 1.22 1.49 0.34 0.87 0.58 
hsa-miR-27a 0.16 1.19 2.02 0.02 0.85 0.94 
hsa-miR-34a 0.66 1.16 1.63 -0.08 0.85 0.73 
miRPlus_17858 0.94 0.82 0.73 0.75 0.81 0.09 
hsa-miR-31 0.31 1.09 1.48 0.27 0.79 0.59 
hsa-miR-24 0.50 1.07 1.32 0.21 0.78 0.51 
hsa-miR-221 0.24 0.50 1.92 0.42 0.77 0.77 
hsa-miR-29c* 0.54 0.96 1.05 0.44 0.75 0.30 
hsa-miR-19b 0.42 0.94 1.04 0.58 0.74 0.29 
miRPlus_17841 0.62 0.24 1.70 0.38 0.74 0.66 
hsa-miR-744 0.44 0.86 1.77 -0.15 0.73 0.81 
hsa-miR-425 0.56 0.59 1.47 0.29 0.73 0.52 
hsa-miR-103 0.50 0.86 1.29 0.21 0.71 0.47 
hsa-miR-30c 0.29 0.76 1.42 0.30 0.69 0.54 
hsa-miR-361-3p 0.28 0.81 1.18 0.47 0.68 0.39 
hsa-miR-877* 0.83 0.66 0.52 0.69 0.68 0.13 
hsa-miR-26b* 0.55 0.73 0.81 0.61 0.67 0.12 
hsa-miR-342-5p 0.14 0.78 1.30 0.41 0.66 0.50 
hsa-miR-652 0.29 0.52 1.10 NA 0.64 0.42 
hsa-miR-181b 0.72 0.83 0.89 0.06 0.63 0.38 
hsa-miR-30d 0.34 0.67 1.15 0.30 0.62 0.39 
hsa-miR-361-5p 0.38 0.65 1.06 0.34 0.61 0.33 
hsa-miR-339-5p 0.21 0.52 1.41 0.28 0.61 0.55 
hsa-let-7d 0.05 0.63 1.75 -0.03 0.60 0.82 
hsa-miR-186 0.27 0.49 1.18 0.46 0.60 0.40 
hsa-miR-106b 0.38 0.72 0.97 0.29 0.59 0.31 
hsa-miR-26a 0.36 0.74 0.66 0.53 0.57 0.17 
hsa-miR-92a 0.18 0.62 1.03 0.41 0.56 0.36 
hsa-miR-136 0.53 0.19 0.89 0.64 0.56 0.29 
hsa-miR-338-5p 0.70 0.49 0.49 NA 0.56 0.12 
hsa-miR-532-5p 0.55 0.62 0.88 0.19 0.56 0.28 
hsa-miR-129* 0.49 0.43 1.45 -0.14 0.56 0.66 
hsa-miR-365 0.31 1.07 0.57 0.22 0.54 0.38 
hsa-miR-140-3p 0.23 0.58 1.08 0.27 0.54 0.39 
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hsa-miR-215 -0.01 0.55 1.46 0.14 0.53 0.66 
hsa-miR-146b-5p 0.37 1.07 0.45 0.24 0.53 0.37 
hsa-miR-331-3p 0.15 0.41 1.65 -0.09 0.53 0.77 
hsa-let-7b 0.31 0.63 0.97 0.15 0.51 0.37 
hsa-miR-484 0.34 0.46 1.10 0.13 0.51 0.42 
hsa-miR-17* 0.31 0.55 0.92 0.22 0.50 0.31 
hsa-miR-93 0.32 0.59 0.99 0.06 0.49 0.40 
hsa-miR-150 0.06 0.57 0.93 0.38 0.49 0.37 
hsa-miR-339-3p NA 0.23 0.73 NA 0.48 0.35 
hsa-miR-519d 0.64 0.52 0.54 0.17 0.47 0.21 
hsa-miR-24-1* NA 0.34 1.01 0.05 0.47 0.49 
hsa-miR-377* 0.54 0.43 0.27 0.60 0.46 0.14 
hsa-miR-340 0.36 0.37 0.80 0.19 0.43 0.26 
hsa-miR-146a 0.21 0.95 0.43 0.10 0.42 0.38 
hsa-miR-193a-3p 0.35 1.33 0.49 -0.52 0.42 0.76 
hsa-miR-296-5p 0.53 0.66 0.16 0.30 0.41 0.22 
hsa-miR-25 0.13 0.47 0.79 0.26 0.41 0.29 
hsa-miR-92b 0.03 0.48 0.88 0.24 0.41 0.36 
hsa-miR-222 -0.10 0.39 1.06 0.24 0.40 0.48 
hsa-miR-500* 0.39 0.55 0.60 0.04 0.40 0.25 
hsa-miR-147 0.12 0.35 0.96 0.14 0.39 0.39 
hsa-miR-502-5p 0.27 0.31 0.55 0.44 0.39 0.13 
hsa-miR-197 0.34 0.36 0.73 0.13 0.39 0.25 
hsa-miR-502-3p 0.19 0.40 0.58 NA 0.39 0.19 
hsa-miR-148b 0.19 0.29 0.91 0.15 0.39 0.36 
hsa-miR-524-5p 0.28 0.57 0.62 0.05 0.38 0.27 
hsa-miR-185 0.53 0.02 0.82 0.12 0.37 0.37 
hsa-miR-26a-2* 0.17 0.33 0.43 0.52 0.36 0.15 
hsa-miR-23a 0.63 0.37 0.46 -0.01 0.36 0.27 
hsa-miR-362-5p 0.36 0.43 0.20 0.41 0.35 0.11 
hsa-miR-191 0.31 0.44 0.61 0.03 0.35 0.24 
hsa-miR-423-3p 0.20 0.29 0.96 -0.10 0.34 0.45 
hsa-miR-138-1* 0.09 0.41 0.81 0.03 0.33 0.35 
hsa-miR-220b 0.49 0.31 0.34 0.19 0.33 0.13 
hsa-miR-620 0.24 0.32 0.55 0.09 0.30 0.19 
hsa-miR-125b -0.18 0.52 0.38 0.41 0.28 0.31 
hsa-miR-142-5p 0.27 0.36 -0.07 0.56 0.28 0.26 
hsa-miR-378 0.71 -0.36 0.21 0.52 0.27 0.47 
hsa-miR-500 0.52 0.24 0.12 0.12 0.25 0.19 
hsa-miR-612 0.34 0.45 0.04 0.15 0.24 0.19 
hsa-miR-337-3p 0.24 0.12 0.37 0.22 0.24 0.10 
hsa-miR-629 0.15 0.19 0.37 NA 0.23 0.12 
hsa-miR-29a 0.08 0.49 -0.02 0.39 0.23 0.24 
hsa-miR-519e 0.19 0.25 0.25 0.18 0.22 0.03 
hsa-miR-125a-5p 0.04 0.98 0.12 -0.31 0.21 0.55 
hsa-miR-34b 0.05 0.03 0.47 0.28 0.21 0.21 
miRPlus_17892 0.35 0.21 0.02 0.20 0.20 0.14 
hsa-let-7c 0.11 0.15 0.45 0.05 0.19 0.18 
hsa-miR-623 0.25 0.19 -0.05 0.37 0.19 0.17 
hsa-miR-505 -0.07 0.16 0.47 NA 0.19 0.27 
hsa-miR-574-3p 0.20 0.17 0.30 0.06 0.18 0.10 
hsa-miR-615-3p 0.36 0.05 -0.04 0.29 0.16 0.19 
hsa-miR-20b* 0.14 NA 0.27 0.09 0.16 0.09 
hsa-miR-486-5p -0.04 -0.18 0.65 0.21 0.16 0.36 
hsa-miR-886-5p -0.13 -0.51 1.04 0.22 0.16 0.66 
hsa-miR-99b 0.11 1.20 0.17 -0.88 0.15 0.85 
hsa-miR-130b 0.05 -0.04 0.51 0.04 0.14 0.25 
hsa-miR-886-3p -0.41 -0.45 0.78 0.62 0.14 0.66 
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hsa-miR-151-3p -0.05 -0.49 0.84 0.25 0.13 0.56 
hsa-miR-374b* 0.24 0.08 0.01 0.18 0.13 0.10 
hsa-miR-202 -0.10 0.17 0.30 NA 0.12 0.21 
hsa-let-7e -0.11 0.22 0.42 -0.05 0.12 0.25 
hsa-miR-106b* 0.04 0.00 0.35 0.05 0.11 0.16 
hsa-miR-768-3p 0.01 0.23 -0.45 0.52 0.08 0.41 
hsa-miR-425* 0.03 -0.05 0.24 NA 0.08 0.15 
hsa-miR-181a 0.50 0.33 -0.37 -0.17 0.07 0.41 
hsa-miR-297 0.36 -0.07 -0.27 0.24 0.06 0.29 
hsa-miR-125a-3p 0.19 0.29 -0.12 -0.13 0.05 0.21 
hsa-miR-22 0.38 0.22 -0.49 0.07 0.04 0.38 
hsa-miR-1 -0.01 -0.17 0.40 -0.09 0.03 0.25 
hsa-miR-518a-3p 0.15 -0.04 -0.07 0.03 0.02 0.10 
hsa-miR-629* 0.13 0.06 -0.05 -0.07 0.02 0.09 
hsa-miR-129-5p -0.03 0.70 -0.33 -0.33 0.00 0.48 
hsa-miR-720 0.56 0.07 -1.04 0.42 0.00 0.72 
hsa-let-7d* 0.15 -0.16 -0.09 0.10 0.00 0.15 
miRPlus_42780 0.02 -0.54 1.00 -0.49 0.00 0.72 
hsa-miR-625* 0.03 0.30 -0.22 -0.15 -0.01 0.23 
hsa-let-7b* -0.14 -0.05 0.26 -0.12 -0.01 0.19 
hsa-miR-600 -0.28 -0.03 0.51 -0.26 -0.01 0.37 
hsa-miR-943 0.07 0.01 -0.05 -0.18 -0.04 0.10 
miRPlus_42856 0.19 -0.25 -0.33 0.20 -0.05 0.28 
hsa-miR-585 0.07 0.50 -0.38 -0.41 -0.05 0.43 
hsa-miR-487b -0.04 -0.02 0.04 -0.22 -0.06 0.11 
hsa-miR-302c* 0.07 -0.06 -0.18 -0.10 -0.07 0.10 
hsa-miR-320a 0.20 -0.36 -0.27 0.15 -0.07 0.29 
hsa-miR-622 -0.01 NA -0.23 0.01 -0.08 0.13 
hsa-miR-147b -0.09 0.98 -1.15 NA -0.09 1.07 
hsa-miR-509-3-5p 0.21 -0.18 -0.54 0.04 -0.12 0.32 
hsa-miR-940 -0.07 0.34 -0.65 NA -0.13 0.49 
hsa-miR-549 -0.03 -0.38 -0.22 0.04 -0.15 0.19 
hsa-miR-553 -0.01 -0.32 NA -0.11 -0.15 0.16 
hsa-miR-584 0.01 -0.01 -0.19 -0.41 -0.15 0.19 
hsa-miR-146b-3p 0.05 -0.21 -0.54 0.04 -0.16 0.28 
hsa-miR-550 -0.19 0.06 -0.66 0.14 -0.16 0.36 
hsa-miR-887 NA -0.19 -0.06 -0.28 -0.18 0.11 
hsa-miR-625 -0.24 -0.52 0.30 -0.28 -0.18 0.35 
hsa-miR-637 -0.13 -0.23 -0.18 -0.29 -0.21 0.07 
hsa-miR-300 0.03 -0.30 -0.25 -0.33 -0.21 0.16 
hsa-miR-885-5p 0.01 -0.36 -0.51 -0.01 -0.22 0.26 
hsa-miR-23a* -0.23 -0.26 -0.17 NA -0.22 0.05 
hsa-miR-576-3p 0.12 -0.50 -0.75 0.17 -0.24 0.46 
hsa-miR-369-3p 0.26 -0.33 -1.07 0.11 -0.26 0.60 
hsa-miR-181a-2* NA -0.43 -0.02 -0.33 -0.26 0.22 
hsa-miR-485-3p -0.25 -0.35 -0.34 -0.16 -0.28 0.09 
hsa-miR-518b -0.07 0.08 -0.70 -0.43 -0.28 0.35 
hsa-miR-99b* -0.30 -0.56 -0.36 0.06 -0.29 0.26 
hsa-miR-766 -0.22 0.16 -0.63 -0.50 -0.30 0.35 
hsa-miR-185* -0.28 -0.59 -0.18 -0.15 -0.30 0.20 
hsa-miR-630 -0.12 -0.40 -0.64 -0.08 -0.31 0.26 
hsa-miR-21* -0.28 -0.05 -0.53 -0.39 -0.31 0.20 
hsa-miR-125b-1* -0.17 -0.43 -0.52 -0.20 -0.33 0.17 
hsa-miR-505* -0.09 -0.55 -0.50 -0.18 -0.33 0.23 
hsa-miR-382 -0.18 -0.54 -0.43 -0.17 -0.33 0.18 
hsa-miR-617 -0.02 -0.51 -0.60 -0.22 -0.34 0.26 
miRPlus_42521 -0.19 0.03 -0.87 -0.35 -0.34 0.38 
hsa-miR-934 -0.13 -0.47 -0.71 -0.14 -0.36 0.28 
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hsa-miR-488 -0.11 -0.43 -0.70 -0.22 -0.36 0.26 
hsa-miR-302d* -0.11 -0.37 -0.71 -0.29 -0.37 0.25 
hsa-miR-423-5p -0.25 -0.53 -0.64 -0.12 -0.38 0.24 
hsa-miR-891a -0.33 -0.53 -0.41 -0.27 -0.39 0.11 
hsa-miR-124 -0.57 -0.61 -0.49 0.13 -0.39 0.35 
hsa-miR-634 -0.23 -0.32 -0.64 -0.36 -0.39 0.17 
hsa-miR-596 -0.20 0.15 -0.88 -0.62 -0.39 0.46 
hsa-miR-877 -0.28 -0.67 -0.37 -0.24 -0.39 0.20 
hsa-miR-642 -0.05 -0.10 -0.97 -0.54 -0.42 0.43 
hsa-miR-206 -0.20 -0.62 -0.66 -0.24 -0.43 0.24 
hsa-miR-185 -0.05 -0.78 -0.73 -0.16 -0.43 0.38 
hsa-miR-516b -0.25 -0.59 -0.69 -0.20 -0.43 0.24 
hsa-miR-184 -0.34 -0.49 -0.87 -0.06 -0.44 0.34 
hsa-miR-187* -0.23 -0.48 -0.89 -0.22 -0.46 0.32 
hsa-miR-155 -0.10 -0.69 -0.90 -0.18 -0.47 0.39 
hsa-miR-638 -0.43 0.27 -1.06 -0.69 -0.48 0.56 
hsa-miR-526b -0.10 -0.65 -0.99 -0.18 -0.48 0.42 
hsa-miR-671-5p -0.49 -0.33 -0.68 -0.43 -0.48 0.15 
hsa-miR-214 -0.31 -0.56 -0.90 -0.17 -0.49 0.32 
hsa-miR-299-3p -0.18 -0.79 -0.83 -0.14 -0.49 0.38 
hsa-miR-525-5p -0.26 -0.21 -1.01 -0.47 -0.49 0.37 
hsa-miR-409-5p 0.00 -0.57 -1.26 -0.15 -0.49 0.56 
hsa-miR-513a-5p 0.02 -0.55 -1.35 -0.11 -0.50 0.62 
hsa-miR-198 -0.42 -0.62 -0.83 -0.17 -0.51 0.28 
hsa-miR-498 -0.33 -0.40 -0.94 -0.39 -0.52 0.29 
hsa-miR-519e* -0.25 -0.65 -0.81 -0.36 -0.52 0.26 
hsa-miR-509-5p -0.19 -0.70 -0.93 -0.27 -0.53 0.35 
hsa-miR-326 -0.41 -1.00 -0.29 -0.44 -0.53 0.32 
hsa-miR-510 -0.29 -0.64 -0.92 -0.29 -0.54 0.30 
hsa-miR-574-5p -0.09 -0.78 -1.19 -0.09 -0.54 0.54 
hsa-miR-483-5p -0.33 -0.79 -0.86 -0.22 -0.55 0.32 
hsa-miR-659 -0.32 -0.70 -0.93 -0.28 -0.56 0.31 
hsa-miR-422a -0.19 -0.63 -1.18 -0.25 -0.56 0.46 
hsa-miR-503 -0.32 -0.58 -1.16 -0.22 -0.57 0.42 
hsa-miR-200b* -0.37 -0.31 -1.15 -0.46 -0.57 0.39 
miRPlus_17955 -0.39 -0.45 -1.03 -0.44 -0.57 0.30 
hsa-miR-490-3p -0.17 -0.78 -1.13 -0.23 -0.58 0.46 
miRPlus_42526 -0.27 -0.46 -1.67 0.08 -0.58 0.76 
hsa-miR-25* -0.49 -0.54 -0.78 -0.52 -0.58 0.14 
hsa-miR-183* -0.53 -0.39 -0.84 -0.56 -0.58 0.19 
hsa-miR-193b* -0.48 -0.80 -0.87 -0.23 -0.60 0.29 
hsa-miR-551a -0.40 -0.84 -0.98 -0.21 -0.61 0.37 
hsa-miR-620 0.35 -0.94 -1.86 -0.04 -0.63 0.99 
hsa-miR-937 -0.56 -0.76 -0.78 -0.45 -0.64 0.16 
hsa-miR-516a-5p -0.45 -1.01 -0.73 -0.36 -0.64 0.29 
hsa-miR-492 -0.87 -0.16 -0.99 -0.54 -0.64 0.37 
hsa-miR-519c-
5p/hsa-miR-519b-
5p/hsa-miR-
523*/hsa-miR-
518e*/hsa-miR-
522*/hsa-miR-
519a* -0.46 -0.48 -1.16 -0.48 -0.64 0.34 
hsa-miR-628-3p -0.42 -0.45 -1.32 -0.54 -0.68 0.43 
hsa-miR-551b* -0.19 -0.88 -1.23 -0.46 -0.69 0.46 
hsa-miR-933 0.03 -0.77 -1.83 -0.19 -0.69 0.83 
miRPlus_42793 -0.48 -0.93 -1.04 -0.33 -0.69 0.34 
hsa-miR-526b* -0.48 -0.86 -1.00 -0.53 -0.72 0.25 
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hsa-miR-765 -0.04 -1.01 -1.68 -0.14 -0.72 0.78 
hsa-miR-663 -0.68 -0.32 -1.48 -0.42 -0.72 0.52 
hsa-miR-520d-5p -0.38 -0.86 -1.11 -0.55 -0.73 0.33 
hsa-miR-939 -0.33 -0.85 -1.41 -0.33 -0.73 0.52 
miRPlus_42745 -0.36 0.12 -1.81 -0.89 -0.73 0.83 
hsa-miR-518a-
5p/hsa-miR-527 -0.35 -0.89 -1.16 -0.54 -0.74 0.36 
hsa-miR-193a-5p -0.24 -0.16 -1.85 -0.70 -0.74 0.78 
hsa-miR-10a* -0.44 -0.87 -1.09 -0.58 -0.75 0.29 
hsa-miR-923 0.58 -1.09 -3.27 0.76 -0.76 1.87 
miRPlus_42487 -0.16 -0.27 -2.33 -0.29 -0.76 1.04 
hsa-miR-583 -0.45 -1.14 -1.16 -0.34 -0.77 0.44 
miRPlus_27560 -0.98 -0.84 -0.95 -0.34 -0.78 0.30 
hsa-miR-542-5p -0.50 -1.22 -1.06 -0.32 -0.78 0.43 
hsa-miR-149* -0.71 -0.77 -1.17 -0.51 -0.79 0.28 
hsa-miR-518c* -0.32 -1.07 -1.54 -0.26 -0.80 0.62 
hsa-miR-874 -0.38 0.09 -1.81 -1.12 -0.80 0.83 
miRPlus_17869 -0.38 -1.12 -1.50 -0.24 -0.81 0.60 
hsa-miR-32* -0.11 -1.07 -1.99 -0.13 -0.83 0.90 
miRPlus_28431 -0.50 -0.35 -1.87 -0.64 -0.84 0.70 
hsa-miR-298 0.17 -1.12 -2.16 -0.26 -0.84 1.03 
hsa-miR-675 -0.84 -0.61 -1.07 -0.87 -0.85 0.19 
hsa-miR-7-2* -0.57 -1.06 -1.32 -0.51 -0.87 0.39 
hsa-miR-658 -0.43 -1.09 -1.59 -0.42 -0.88 0.57 
hsa-miR-30b* -0.60 -0.85 -1.82 -0.39 -0.91 0.63 
hsa-miR-557 -0.58 -0.35 -1.83 -0.92 -0.92 0.65 
hsa-miR-30c-1* -0.64 -1.28 -1.24 -0.69 -0.96 0.35 
hsa-miR-665 -0.51 -1.06 -2.05 -0.44 -1.01 0.74 
hsa-miR-30c-2* -0.53 -1.52 -1.76 -0.36 -1.04 0.70 
hsa-miR-602 -0.54 -1.03 -2.13 -0.59 -1.07 0.74 
hsa-miR-551b -0.56 -1.45 -1.85 -0.48 -1.09 0.67 
hsa-miR-640 -0.81 -1.27 -1.54 -0.73 -1.09 0.39 
hsa-miR-631 -0.84 -1.39 -1.68 -0.70 -1.15 0.46 
hsa-miR-552 -0.50 -1.56 -2.19 -0.38 -1.16 0.87 
hsa-miR-371-5p -0.55 -0.31 -2.71 -1.09 -1.17 1.08 
hsa-miR-921 -0.53 -1.48 -2.26 -0.42 -1.17 0.87 
hsa-miR-381 -0.43 -1.57 -2.34 -0.45 -1.20 0.93 
hsa-miR-494 -0.31 -1.68 -3.04 -0.43 -1.37 1.28 
miRPlus_17952 -1.28 -3.28 -5.31 -1.15 -2.75 1.96 
 
miR indicates microRNA; SD, standard deviation;  
A particular microRNA that failed on an array is indicated by the acronym "NA". 
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B, Median Hy3 and Hy5 signal 	  
  Healthy 1 Healthy 2 Healthy 3 Healthy 4 
  median Hy3 median Hy5 median Hy3 median Hy5 median Hy3 median Hy5 median Hy3 median Hy5 
hsa-let-7f 46.9 35.0 136.6 40.2 518.3 29.4 44.0 39.3 
hsa-miR-32 48.8 33.3 141.7 31.5 462.2 21.3 65.4 37.1 
hsa-miR-16 1039.0 420.6 2925.1 510.3 5775.3 581.0 744.0 320.5 
hsa-miR-20b 44.9 39.3 156.6 39.3 377.2 29.5 50.3 36.9 
hsa-miR-335 39.2 43.9 68.1 47.8 319.5 32.4 42.7 39.8 
hsa-miR-301a 50.5 39.9 96.6 37.9 294.8 30.5 45.4 35.5 
hsa-miR-30e* 87.3 46.4 177.8 53.3 390.9 42.4 88.9 52.3 
hsa-miR-142-3p 5425.4 2932.4 16290.7 3935.1 20887.8 4422.5 6107.7 2546.1 
hsa-miR-27b 305.5 192.9 880.0 238.3 2266.3 207.2 245.9 177.6 
hsa-miR-30e 450.2 254.5 1088.3 319.6 2250.4 285.8 464.9 239.7 
hsa-miR-374a 382.9 206.3 894.6 255.7 1883.1 261.7 294.8 171.9 
hsa-miR-140-5p 90.3 53.3 216.6 59.8 401.8 49.0 148.8 103.9 
hsa-miR-19a 546.9 313.5 1396.0 404.2 2140.0 342.2 566.9 329.6 
hsa-let-7a 352.6 228.0 989.1 257.1 2209.3 280.1 239.7 179.3 
hsa-miR-126 63.7 62.4 68.2 74.3 2051.4 57.7 86.4 50.2 
hsa-miR-130a 62.8 51.7 73.1 59.1 801.3 43.6 75.3 46.8 
hsa-miR-17 266.7 177.5 657.1 224.3 1299.6 215.6 229.8 151.8 
hsa-miR-106a 266.9 181.3 647.3 214.2 1244.8 214.3 219.2 142.7 
hsa-miR-98 47.4 41.3 97.5 46.3 216.3 38.2 51.0 40.0 
hsa-miR-29b 1549.9 1047.7 4216.2 1337.6 5190.3 1174.9 1675.1 989.2 
hsa-miR-18b 97.2 60.2 176.4 68.3 324.2 52.7 70.4 56.2 
hsa-let-7g 117.3 99.2 312.7 103.2 584.3 86.6 117.5 89.6 
hsa-miR-26b 1803.5 1260.1 4652.7 1605.0 8389.6 2047.6 1709.3 985.4 
hsa-miR-363* 69.1 33.5 94.8 44.8 128.4 36.6 72.5 40.9 
hsa-miR-23b 1049.8 645.6 2091.5 888.2 4705.8 960.3 833.6 611.5 
hsa-miR-15a 777.5 450.6 1622.4 568.9 2275.3 590.0 500.0 372.3 
hsa-miR-101 772.1 523.2 1864.0 657.8 2378.3 682.2 744.0 436.0 
hsa-miR-29a* 74.5 46.3 135.5 50.4 174.8 44.7 70.8 47.5 
hsa-miR-668 148.8 100.8 291.9 119.7 479.5 97.6 119.7 95.3 
hsa-miR-15b 416.9 298.3 915.5 377.4 1802.6 384.1 355.8 251.0 
hsa-miR-154 241.7 167.3 491.8 204.3 952.2 182.7 188.9 149.7 
hsa-miR-18a 93.9 64.0 180.5 71.1 342.5 64.0 60.5 55.9 
hsa-miR-374b 105.3 78.6 212.6 90.5 380.4 69.2 90.3 77.1 
hsa-miR-20a 499.8 376.9 1125.6 450.2 2243.4 482.2 440.0 318.1 
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hsa-miR-616* 51.1 27.2 51.3 24.4 51.2 22.9 52.4 25.6 
hsa-miR-768-5p 402.4 368.8 1065.6 434.8 2118.0 469.4 436.0 291.3 
hsa-miR-33a 68.2 58.1 138.8 66.3 262.4 56.6 92.7 53.5 
hsa-miR-105 226.0 136.7 445.1 155.5 442.6 126.0 142.8 131.0 
hsa-miR-28-5p 82.7 65.9 147.2 73.4 360.1 60.6 68.2 57.2 
hsa-miR-148a 46.2 47.8 71.3 48.0 115.8 40.7 48.0 43.7 
hsa-miR-7 53.3 37.1 76.2 39.0 116.1 32.1 55.7 35.8 
hsa-miR-195 54.9 43.5 98.0 49.9 188.1 37.6 55.0 46.1 
hsa-miR-424 158.7 109.9 299.3 127.2 417.6 125.2 128.0 94.5 
hsa-miR-342-3p 632.4 533.4 1597.1 679.5 2434.7 735.9 672.8 437.0 
hsa-miR-483-3p 91.0 39.6 67.0 39.1 62.0 31.6 61.3 32.2 
hsa-miR-223 2003.7 1209.9 3303.5 1502.8 6544.9 1854.4 999.2 938.8 
hsa-miR-22* 89.0 63.1 149.9 68.9 221.0 59.2 69.7 62.0 
hsa-miR-199a-5p 66.7 54.0 53.0 65.0 358.2 52.4 75.9 44.4 
hsa-miR-107 216.9 162.4 394.6 201.5 665.4 167.2 181.8 159.6 
hsa-miR-150* 46.0 42.5 72.9 48.6 104.4 43.6 44.8 43.9 
hsa-miR-194 56.5 42.7 104.0 54.9 152.1 43.1 65.6 48.2 
hsa-miR-21 6332.2 3176.6 12406.8 4284.8 8700.8 5523.0 3606.1 2806.7 
hsa-miR-30b 631.0 532.6 1380.5 657.7 2749.2 697.3 537.9 448.0 
hsa-miR-338-3p 246.9 123.2 480.5 137.4 306.2 116.9 74.5 116.1 
hsa-let-7i 546.1 417.5 1227.1 541.7 1570.8 556.5 450.7 356.5 
hsa-miR-27a 697.4 628.6 1734.6 756.0 3130.4 781.3 552.1 543.1 
hsa-miR-34a 283.8 169.8 436.7 196.4 560.6 178.9 135.8 145.3 
miRPlus_17858 81.2 42.9 74.4 41.9 68.1 41.1 58.4 33.8 
hsa-miR-31 71.8 58.2 133.0 62.8 160.9 58.4 60.6 50.3 
hsa-miR-24 1516.8 1043.5 2804.1 1334.7 4073.4 1647.6 1039.5 887.0 
hsa-miR-221 165.9 140.5 239.8 169.1 549.9 141.5 187.1 137.2 
hsa-miR-29c* 65.3 45.0 95.6 48.8 97.4 46.6 59.5 42.6 
hsa-miR-19b 1136.7 825.3 2029.0 1081.5 2131.0 1061.2 1198.5 802.9 
miRPlus_17841 65.3 42.9 62.0 52.9 137.6 41.8 58.3 44.6 
hsa-miR-744 97.3 70.6 145.5 80.3 255.1 73.8 59.5 66.1 
hsa-miR-425 169.9 113.5 196.9 128.3 325.0 116.3 125.7 102.8 
hsa-miR-103 576.6 405.4 848.5 465.8 1225.7 490.4 383.7 332.8 
hsa-miR-30c 647.8 530.1 1061.2 626.0 1720.1 641.7 533.3 445.8 
hsa-miR-361-3p 127.1 105.6 203.8 115.8 222.2 95.8 136.3 97.5 
hsa-miR-877* 60.7 33.8 62.4 38.5 51.7 36.0 53.3 33.0 
hsa-miR-26b* 56.2 39.4 71.0 42.9 73.6 42.0 56.9 36.7 
hsa-miR-342-5p 101.4 92.2 172.8 100.8 232.1 95.6 105.7 76.2 
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hsa-miR-652 57.6 47.0 77.4 53.7 110.5 51.0 40.0 45.7 
hsa-miR-181b 165.2 99.3 205.9 114.0 176.6 94.7 108.4 104.7 
hsa-miR-30d 405.3 319.3 591.2 378.1 798.3 359.5 328.2 262.9 
hsa-miR-361-5p 313.2 241.4 425.6 272.0 554.5 264.1 243.5 191.0 
hsa-miR-339-5p 198.5 173.5 287.0 199.9 518.2 197.5 165.1 135.5 
hsa-let-7d 100.0 96.8 167.8 109.0 324.5 96.4 90.0 91.7 
hsa-miR-186 212.1 178.8 300.3 215.4 428.0 190.5 204.8 151.0 
hsa-miR-106b 823.4 633.7 1269.6 755.8 1729.5 881.0 578.4 464.4 
hsa-miR-26a 2510.5 1972.9 4616.7 2693.1 5299.5 3385.0 2363.6 1623.2 
hsa-miR-92a 111.2 97.5 158.9 102.8 188.6 92.1 122.1 91.9 
hsa-miR-136 78.3 54.2 69.1 60.5 96.9 52.2 80.6 51.1 
hsa-miR-338-5p 61.2 38.4 63.4 46.2 58.0 41.8 48.6 38.0 
hsa-miR-532-5p 71.2 51.1 89.1 58.5 91.3 50.8 54.0 47.6 
hsa-miR-129* 77.5 55.9 80.8 59.0 134.4 49.8 49.3 54.4 
hsa-miR-365 62.5 49.2 124.2 59.0 79.0 53.2 104.0 78.3 
hsa-miR-140-3p 529.0 452.3 786.2 521.9 1134.7 537.7 427.8 350.0 
hsa-miR-215 73.9 75.4 126.3 87.5 179.7 68.8 94.0 84.7 
hsa-miR-146b-5p 1268.3 994.0 2571.8 1195.4 1870.1 1372.7 871.4 755.9 
hsa-miR-331-3p 81.8 71.3 110.4 83.1 231.6 74.1 62.4 66.5 
hsa-let-7b 289.9 236.5 436.5 278.9 560.6 283.1 202.2 182.0 
hsa-miR-484 78.5 65.5 97.4 71.1 135.6 65.4 62.6 58.1 
hsa-miR-17* 72.7 59.5 102.1 69.3 115.5 61.8 68.3 58.9 
hsa-miR-93 312.1 250.9 441.6 293.8 594.0 293.1 225.2 216.5 
hsa-miR-150 769.1 704.6 1358.4 932.3 1791.3 943.6 760.5 590.8 
hsa-miR-339-3p 43.1 47.1 65.4 55.0 78.6 47.7 38.0 43.8 
hsa-miR-519d 708.2 454.9 775.3 532.8 724.4 496.3 476.0 427.4 
hsa-miR-24-1* 117.4 108.5 143.9 113.5 209.4 106.3 105.7 100.7 
hsa-miR-377* 56.0 38.5 64.5 46.9 56.3 45.8 70.9 46.8 
hsa-miR-340 375.9 295.8 456.1 355.8 541.1 311.5 305.5 266.7 
hsa-miR-146a 706.8 609.9 1384.1 720.2 1040.0 773.1 516.5 485.9 
hsa-miR-193a-3p 172.8 136.7 399.8 156.5 203.8 144.1 80.7 113.9 
hsa-miR-296-5p 59.7 42.9 77.1 50.1 52.5 47.1 164.0 132.7 
hsa-miR-25 269.7 242.7 392.8 285.8 444.9 259.5 253.9 212.4 
hsa-miR-92b 63.1 62.9 97.1 68.4 108.0 58.3 70.2 61.1 
hsa-miR-222 354.2 379.9 585.5 443.0 934.0 451.2 375.5 313.7 
hsa-miR-500* 101.2 78.2 128.6 88.9 124.9 83.8 74.5 72.9 
hsa-miR-147 57.8 54.9 78.4 60.6 102.7 51.7 58.3 52.5 
hsa-miR-502-5p 51.8 42.7 56.7 45.9 55.5 38.6 54.4 39.8 
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hsa-miR-197 129.0 102.8 141.3 108.9 165.0 101.0 99.1 91.6 
hsa-miR-502-3p 65.4 57.4 83.7 64.7 84.4 55.9 47.3 51.7 
hsa-miR-148b 264.5 233.4 336.3 278.7 484.3 258.7 207.7 185.4 
hsa-miR-524-5p 130.8 107.6 186.0 125.9 165.8 107.8 110.3 104.8 
hsa-miR-185 484.1 337.9 390.2 388.6 695.3 397.4 292.4 269.3 
hsa-miR-26a-2* 90.7 81.3 112.6 89.0 117.0 87.6 94.5 68.3 
hsa-miR-23a 2848.4 1832.4 3082.9 2361.5 4209.0 3087.5 1440.2 1455.3 
hsa-miR-362-5p 71.8 55.7 87.1 64.5 71.7 62.2 116.6 65.0 
hsa-miR-191 1016.4 822.8 1435.2 1063.5 1790.0 1153.8 667.9 657.4 
hsa-miR-423-3p 309.0 268.2 402.1 328.1 594.6 307.0 215.3 228.9 
hsa-miR-138-1* 193.4 182.2 296.6 226.0 318.5 182.3 203.9 199.9 
hsa-miR-220b 84.7 60.6 93.4 78.6 82.6 67.5 74.8 66.0 
hsa-miR-620 311.1 262.8 343.1 280.7 375.4 256.8 302.3 279.6 
hsa-miR-125b 59.9 67.9 117.4 83.1 96.0 74.3 108.7 80.9 
hsa-miR-142-5p 7052.0 5871.2 11634.5 9239.2 11707.6 12362.2 6831.6 4618.1 
hsa-miR-378 569.2 352.4 331.8 427.9 479.7 408.8 394.7 275.0 
hsa-miR-500 73.8 51.5 74.0 59.5 64.2 59.3 51.7 47.9 
hsa-miR-612 60.7 45.5 74.0 53.4 51.8 51.6 53.3 49.3 
hsa-miR-337-3p 56.2 47.5 56.7 54.9 62.4 48.6 57.8 49.7 
hsa-miR-629 55.1 49.5 63.9 57.5 66.9 51.8 48.6 53.2 
hsa-miR-29a 4545.9 4342.5 8192.9 5940.8 7857.6 7686.1 4484.4 3451.1 
hsa-miR-519e 54.0 47.8 65.4 56.4 65.4 54.8 51.6 45.3 
hsa-miR-125a-5p 574.9 560.4 1296.9 654.7 760.7 688.8 379.3 469.3 
hsa-miR-34b 623.5 615.9 703.7 684.7 932.1 681.9 665.4 555.7 
miRPlus_17892 67.0 52.4 66.4 57.8 55.6 53.9 58.9 50.4 
hsa-let-7c 555.0 521.9 746.9 668.2 928.7 680.3 506.5 488.2 
hsa-miR-623 61.5 51.5 63.5 56.1 53.9 55.2 63.8 49.9 
hsa-miR-505 57.4 60.2 75.9 69.0 86.5 62.6 46.7 54.7 
hsa-miR-574-3p 154.1 135.5 173.4 154.9 167.3 136.3 133.8 127.8 
hsa-miR-615-3p 73.3 59.2 67.7 65.1 62.9 63.6 69.8 56.3 
hsa-miR-20b* 90.7 83.6 128.6 88.9 97.3 80.8 89.9 83.1 
hsa-miR-486-5p 52.9 54.0 53.8 61.3 84.4 54.8 53.5 46.2 
hsa-miR-886-5p 79.8 89.7 76.2 109.4 187.3 91.7 107.0 85.4 
hsa-miR-99b 154.4 149.8 370.5 162.6 170.5 152.8 69.6 129.3 
hsa-miR-130b 112.0 108.4 123.0 122.4 156.4 110.0 104.1 102.1 
hsa-miR-886-3p 159.8 210.2 184.4 251.9 414.3 244.6 248.7 165.3 
hsa-miR-151-3p 63.7 65.8 54.2 76.5 121.7 68.2 67.4 58.0 
hsa-miR-374b* 118.9 100.7 115.5 110.0 111.1 110.6 99.6 90.2 
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hsa-miR-202 53.4 59.1 78.9 69.1 73.6 57.8 45.6 64.8 
hsa-let-7e 830.1 895.9 1228.2 1065.2 1516.2 1133.5 810.7 858.1 
hsa-miR-106b* 69.2 67.5 83.5 79.6 93.2 73.0 72.1 69.6 
hsa-miR-768-3p 3635.8 3600.4 5290.9 4555.6 4396.6 6145.3 3898.9 2708.7 
hsa-miR-425* 57.0 56.5 56.9 58.8 64.7 54.6 48.4 51.8 
hsa-miR-181a 1057.5 737.9 1188.6 962.8 687.1 889.6 683.3 777.6 
hsa-miR-297 117.7 94.6 100.8 105.3 74.3 87.6 117.5 100.6 
hsa-miR-125a-3p 60.9 53.8 81.8 66.4 56.3 61.4 55.3 58.8 
hsa-miR-22 3179.8 2510.1 3712.9 3183.4 3048.8 4281.3 2116.7 1995.8 
hsa-miR-1 147.5 147.8 150.4 167.7 172.7 131.0 164.1 177.4 
hsa-miR-518a-3p 54.4 48.9 54.9 58.2 50.0 53.5 49.6 53.9 
hsa-miR-629* 59.7 54.7 62.7 60.7 53.5 55.9 53.8 56.2 
hsa-miR-129-5p 225.2 228.7 394.7 247.8 170.6 210.9 188.8 235.3 
hsa-miR-720 9025.5 6184.3 8810.5 8035.6 6341.5 13072.4 6212.1 4667.8 
hsa-let-7d* 91.5 81.3 88.0 98.1 80.2 85.6 85.5 76.7 
miRPlus_42780 83.2 83.1 66.7 96.6 167.2 83.5 52.8 73.8 
hsa-miR-625* 259.9 253.4 352.2 283.6 212.9 253.5 217.6 240.3 
hsa-let-7b* 48.2 54.9 58.9 61.0 66.9 55.7 49.5 53.0 
hsa-miR-600 55.8 69.8 72.9 74.6 84.1 59.3 57.4 68.6 
hsa-miR-943 118.3 109.5 132.9 131.7 101.9 105.0 101.9 111.3 
miRPlus_42856 983.1 845.3 871.1 1039.9 877.0 1096.5 811.7 682.8 
hsa-miR-585 72.9 70.1 91.0 64.3 48.3 62.2 63.0 84.4 
hsa-miR-487b 239.3 245.2 287.5 287.2 255.6 249.0 213.4 246.8 
hsa-miR-302c* 61.4 58.8 65.7 69.0 53.6 60.8 60.1 62.7 
hsa-miR-320a 839.2 750.2 714.5 913.5 818.9 993.5 623.0 568.8 
hsa-miR-622 58.9 59.1 47.4 68.7 48.4 57.1 60.4 60.1 
hsa-miR-147b 62.0 66.7 140.6 70.4 38.0 84.6 38.6 58.7 
hsa-miR-509-3-5p 260.4 225.0 237.7 258.9 158.6 227.8 215.9 201.1 
hsa-miR-940 60.6 62.5 89.2 67.5 43.2 69.9 41.3 60.9 
hsa-miR-549 505.2 514.9 459.3 586.9 478.6 552.5 451.4 444.0 
hsa-miR-553 53.7 54.9 52.4 66.8 44.6 58.4 51.9 55.5 
hsa-miR-584 171.0 167.1 192.6 192.2 140.9 161.1 123.1 163.4 
hsa-miR-146b-3p 189.5 182.9 175.2 201.9 122.1 175.8 170.2 165.0 
hsa-miR-550 3098.9 3512.3 4805.2 4687.0 3900.4 6078.0 2827.0 2596.0 
hsa-miR-887 188.2 184.3 180.5 205.7 171.5 179.3 149.3 180.8 
hsa-miR-625 122.9 145.0 118.7 170.0 181.7 146.0 122.5 147.4 
hsa-miR-637 109.1 119.3 106.2 123.6 95.3 108.7 101.4 124.1 
hsa-miR-300 530.5 517.7 488.8 598.1 478.0 569.4 385.2 481.9 
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hsa-miR-885-5p 121.1 121.1 112.3 138.1 87.8 128.4 114.2 113.0 
hsa-miR-23a* 45.9 54.6 54.5 64.6 50.9 57.5 45.5 53.8 
hsa-miR-576-3p 599.4 544.3 423.8 573.1 311.6 524.1 591.2 518.3 
hsa-miR-369-3p 97.2 81.8 74.1 93.8 43.7 90.1 93.7 86.7 
hsa-miR-181a-2* 61.7 83.8 52.7 71.1 60.4 61.2 54.6 74.2 
hsa-miR-485-3p 112.2 132.5 113.8 145.1 113.4 141.9 106.8 118.0 
hsa-miR-518b 76.1 82.5 94.3 89.3 49.7 80.6 57.6 77.7 
hsa-miR-99b* 117.1 144.9 114.7 165.4 106.5 136.9 155.9 154.4 
hsa-miR-766 152.2 180.4 235.8 211.7 127.9 195.5 111.2 157.5 
hsa-miR-185* 212.8 253.3 195.8 294.8 220.0 249.8 232.0 255.1 
hsa-miR-630 113.4 119.3 102.0 134.8 82.5 127.5 110.7 117.8 
hsa-miR-21* 184.9 224.2 238.6 249.5 176.2 251.8 136.9 183.2 
hsa-miR-125b-1* 75.5 80.1 71.2 96.7 61.2 88.5 81.8 94.3 
hsa-miR-505* 139.9 153.5 125.4 182.4 109.8 158.0 136.9 155.4 
hsa-miR-382 84.2 98.0 74.7 110.3 66.7 90.3 87.0 97.0 
hsa-miR-617 119.1 120.9 95.2 135.6 81.1 123.5 105.6 118.6 
miRPlus_42521 413.6 473.8 508.0 493.5 237.6 429.2 417.4 533.8 
hsa-miR-934 139.3 160.0 124.5 169.5 90.6 148.9 128.5 143.7 
hsa-miR-488 62.4 68.5 60.1 81.3 46.0 76.3 63.3 71.8 
hsa-miR-302d* 408.1 451.2 428.7 547.9 307.8 500.2 293.9 367.0 
hsa-miR-423-5p 921.6 1104.3 954.3 1368.0 892.4 1389.3 904.4 978.3 
hsa-miR-891a 133.4 167.0 129.6 188.3 116.9 157.9 142.3 173.6 
hsa-miR-124 45.7 65.3 51.5 78.8 51.9 73.3 63.2 58.7 
hsa-miR-634 438.3 514.0 508.3 625.4 335.6 537.6 417.7 529.3 
hsa-miR-596 58.2 66.9 86.5 76.6 39.6 70.9 47.1 72.7 
hsa-miR-877 128.2 154.6 108.4 171.5 113.9 146.9 143.1 166.7 
hsa-miR-642 791.7 820.1 767.9 833.2 363.9 718.2 551.2 804.8 
hsa-miR-206 65.2 74.9 52.8 81.1 42.2 66.8 66.3 78.6 
hsa-miR-185 1048.3 1125.9 765.4 1310.1 797.4 1311.5 950.8 1067.7 
hsa-miR-516b 97.0 112.6 89.9 137.6 71.3 114.2 109.4 124.3 
hsa-miR-184 321.3 410.0 347.0 479.8 217.8 386.0 451.6 471.2 
hsa-miR-187* 132.4 151.7 123.3 169.9 80.1 150.4 134.6 160.9 
hsa-miR-155 785.9 831.1 657.0 1055.5 541.3 1000.0 789.7 894.0 
hsa-miR-638 237.5 318.7 376.0 303.8 132.3 275.1 204.3 330.5 
hsa-miR-526b 112.7 120.5 92.1 144.6 66.2 131.3 112.1 126.6 
hsa-miR-671-5p 69.2 96.8 86.7 110.1 64.3 101.4 72.3 98.3 
hsa-miR-214 132.8 164.8 131.7 197.7 93.2 173.8 148.9 167.9 
hsa-miR-299-3p 93.4 105.8 71.7 126.9 57.0 100.4 108.9 119.3 
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hsa-miR-525-5p 157.7 189.6 180.0 205.5 94.4 188.8 132.9 183.7 
hsa-miR-409-5p 119.8 119.6 93.4 141.9 50.9 124.0 113.9 128.5 
hsa-miR-513a-5p 1101.8 1077.4 840.3 1234.2 482.1 1213.3 1062.0 1148.1 
hsa-miR-198 94.7 128.4 94.9 143.8 75.1 129.6 117.0 132.3 
hsa-miR-498 159.5 200.2 166.5 211.9 105.0 202.7 140.6 184.4 
hsa-miR-519e* 184.4 219.8 158.3 253.3 128.0 223.6 160.3 204.4 
hsa-miR-509-5p 183.1 212.1 153.2 248.9 120.2 230.2 158.1 191.1 
hsa-miR-326 121.6 161.5 92.7 188.1 128.4 156.8 111.8 150.8 
hsa-miR-510 106.9 130.8 99.0 157.9 77.6 145.8 112.5 134.9 
hsa-miR-574-5p 871.9 947.6 629.4 1075.6 429.3 976.3 697.3 767.4 
hsa-miR-483-5p 126.7 160.3 95.4 169.9 82.8 150.4 141.4 167.1 
hsa-miR-659 93.1 117.4 82.4 133.8 65.0 121.1 93.7 112.5 
hsa-miR-422a 220.1 244.3 183.1 279.2 108.9 246.4 204.8 242.0 
hsa-miR-503 949.4 1157.6 914.8 1363.8 617.6 1368.3 903.9 1053.0 
hsa-miR-200b* 84.6 108.3 94.8 119.1 52.2 115.7 77.8 108.6 
miRPlus_17955 135.4 176.8 143.7 195.9 80.9 162.9 131.2 177.5 
hsa-miR-490-3p 83.2 94.8 65.4 110.8 46.9 105.5 72.5 86.0 
miRPlus_42526 2404.9 2905.1 2450.6 3401.2 1299.5 4122.5 2844.6 2708.5 
hsa-miR-25* 164.1 230.1 167.3 246.0 143.7 249.3 213.3 300.5 
hsa-miR-183* 141.1 199.9 173.7 226.5 114.0 202.9 128.8 188.3 
hsa-miR-193b* 76.4 109.0 75.4 130.9 63.8 117.0 93.7 110.7 
hsa-miR-551a 99.5 132.3 87.7 156.5 68.7 138.6 157.8 179.1 
hsa-miR-620 3113.9 2511.6 1524.4 2929.5 701.6 2552.8 2579.7 2668.5 
hsa-miR-937 65.2 95.9 73.3 116.0 60.4 100.6 80.7 111.0 
hsa-miR-516a-5p 261.9 358.6 208.3 416.7 207.5 342.2 272.1 350.1 
hsa-miR-492 67.3 120.6 121.6 134.9 59.0 118.6 95.9 137.2 
hsa-miR-519c-
5p/hsa-miR-519b-
5p/hsa-miR-
523*/hsa-miR-
518e*/hsa-miR-
522*/hsa-miR-
519a* 146.4 201.5 167.3 233.3 89.5 199.0 142.3 199.2 
hsa-miR-628-3p 746.8 1007.9 910.8 1258.9 542.2 1344.5 631.4 907.1 
hsa-miR-551b* 133.9 153.1 104.3 190.6 71.4 167.2 120.9 163.3 
hsa-miR-933 3634.1 3547.4 2678.7 4632.9 1463.8 5010.2 3012.1 3356.8 
miRPlus_42793 336.9 467.5 282.2 532.7 222.2 457.8 341.2 426.8 
hsa-miR-526b* 50.4 73.7 51.1 89.7 41.7 85.2 54.2 78.8 
hsa-miR-765 1282.7 1379.0 857.3 1715.0 524.5 1657.0 1215.1 1353.7 
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hsa-miR-663 52.8 81.6 70.3 87.1 30.6 86.4 65.7 87.2 
hsa-miR-520d-5p 583.4 755.5 530.1 937.4 399.2 852.0 450.4 656.5 
hsa-miR-939 777.5 974.4 689.2 1276.5 455.0 1208.1 674.6 839.2 
miRPlus_42745 866.1 1097.5 1503.3 1381.2 420.3 1478.9 628.9 1164.2 
hsa-miR-518a-
5p/hsa-miR-527 276.3 346.9 215.9 402.8 151.4 341.2 230.5 336.8 
hsa-miR-193a-5p 1665.2 1972.1 2142.9 2399.1 706.4 2531.2 1131.7 1867.6 
hsa-miR-10a* 46.7 63.4 42.2 77.1 34.9 74.6 50.1 75.5 
hsa-miR-923 14867.2 9951.6 7596.3 15887.3 2582.3 25041.1 15427.1 9207.8 
miRPlus_42487 9879.3 10915.0 10428.4 12840.7 3738.7 18320.5 7707.9 9438.5 
hsa-miR-583 454.6 612.4 338.5 747.2 304.9 681.7 509.8 641.7 
miRPlus_27560 197.1 387.0 235.6 421.3 188.2 364.0 340.3 429.1 
hsa-miR-542-5p 73.4 102.4 52.4 123.9 49.6 103.7 100.1 124.3 
hsa-miR-149* 355.5 580.0 419.7 720.4 320.7 722.3 327.1 471.5 
hsa-miR-518c* 732.4 902.3 524.7 1101.5 356.9 1037.6 674.2 814.3 
hsa-miR-874 373.6 486.3 645.2 603.1 146.3 510.0 205.0 444.0 
miRPlus_17869 1344.9 1771.9 1055.8 2369.5 830.9 2335.7 1592.1 1871.4 
hsa-miR-32* 2029.8 2288.9 1313.9 2731.1 743.0 2966.4 1713.9 1869.9 
miRPlus_28431 1701.9 2410.6 2121.6 2748.9 856.9 3101.5 1534.7 2381.2 
hsa-miR-298 1029.4 926.6 530.1 1154.4 208.4 924.5 788.0 954.7 
hsa-miR-675 112.3 203.2 150.5 230.2 93.7 201.1 121.7 219.0 
hsa-miR-7-2* 68.9 101.0 57.1 120.8 40.9 102.4 74.9 107.6 
hsa-miR-658 784.0 1054.2 613.9 1284.0 421.0 1256.9 761.1 1000.9 
hsa-miR-30b* 1157.9 1738.8 1120.4 2019.1 569.7 2009.7 1216.6 1605.5 
hsa-miR-557 66.3 96.7 81.6 102.6 31.2 109.4 54.5 99.1 
hsa-miR-30c-1* 82.4 128.9 61.0 147.7 52.9 127.5 87.9 141.2 
hsa-miR-665 1263.5 1758.9 1092.6 2229.2 537.9 2228.1 1157.6 1564.9 
hsa-miR-30c-2* 758.1 1091.0 504.0 1463.0 438.5 1475.3 784.9 1020.1 
hsa-miR-602 435.2 646.0 411.2 837.2 146.9 656.9 496.3 746.9 
hsa-miR-551b 1304.0 1860.3 846.3 2331.3 654.2 2320.5 1148.5 1599.3 
hsa-miR-640 65.9 116.1 56.7 137.8 40.1 117.5 74.5 123.4 
hsa-miR-631 47.0 81.8 37.8 99.0 28.6 88.2 49.9 81.0 
hsa-miR-552 142.0 193.1 84.0 248.7 46.4 211.0 171.5 215.2 
hsa-miR-371-5p 2970.7 4341.8 4762.3 6237.0 1203.9 7904.4 1898.2 4030.6 
hsa-miR-921 1373.2 1993.7 989.8 2697.9 552.8 2683.2 1485.2 1949.4 
hsa-miR-381 412.9 558.0 226.2 668.5 103.4 534.4 390.8 534.0 
hsa-miR-494 3419.3 4205.0 1752.0 5739.3 654.0 5342.7 3177.8 4387.9 
miRPlus_17952 9573.6 23388.1 3424.2 32527.3 1020.0 40380.7 9359.0 20890.0 
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Supplemental Table 5. Sequences for anti-miRs 
Name Sequence  
hsa-miR-126 5’-CGCATTATTACTCACGGTACGA-3’ 
hsa-miR-130a 5’-ATGCCCTTTTAACATTGCACTG-3’ 
 
 
 
Supplemental Table 6. Sequences for miR-mimics 
Name Sequence  
hsa-miR-126 5’-UCGUACCGUGAGUAAUAAUGCG-3’ 
hsa-miR-130a 5’- CAGUGCAAUGUUAAAAGGGCAU-3’ 
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Supplemental Table 7. Sequences of primers for quantitative real time PCR 
Name Forward sequence Reverse sequence 
Spred1 5’-CGGCGACTTCTGACAACGAT-3’ 5’-TTGAGTCATCTCGGGTCATCAC-3’ 
HOXA5 5’-TCTCGTTGCCCTAATTCATCTTT-3’ 5’-CATTCAGGACAAAGAGATGAACAGAA-3’ 
EGFL7 5’–CAGACGGTACACTCTGTGTGC–3’ 5’–CAGCACCAGCTGCAGCTTCT–3’ 
hL28 5’–GCATCTGCAATGGATGGT–3’ 5’-CCTTTCTCCTGGCCCATACAC–3’ 
TBP 5’-TGCACAGGAGCCAAGAGTAA-3’ 5’-CACATCACAGCTCCCCACCA-3’ 
GAPDH 5’– GAAGGTGAAGGTCGGAGTC –3’ 5’– GAAGATGGTGATGGGATTTC –3’ 
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